

520 Rec'd PCT/PTO 2 2 OCT 1999

Express Mail Label No.:
EEL371022988US

FORM PTO-1390 (REV. 11-94)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				20239-706	
INTERNATIONAL APPLICATION NO. PCT/EP98/02341		INTERNATIONAL FILING DATE April 21, 1998		U.S. APPLICATION NO. (If known, see 37 CFR 1.1) Not Yet Assigned 09/403690	
TITLE OF INVENTION TaqMan™-PCR for the Detection of Pathogenic E. Coli Strains				PRIORITY DATE CLAIMED April 22, 1997	
APPLICANT(S) FOR DO/EO/US Bavarian Nordic Research Institute A/S					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unsigned) <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11. to 16. below concern document(s) or information included:					
<ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: Copies of: <ol style="list-style-type: none"> Article 34 Amendment to Claims Submitted July 12, 1999 to IPEA (14 pgs.) International Search Report (8 pgs.) PCT Request (3 pgs.) 					

514 Rec'd PCT/PTO 22 OCT 1999

09/403690

U.S. APPLICATION NO. 09/403690
Not Yet Assigned

INTERNATIONAL APPLICATION NO.
PCT/EP98/02341

TRANSMITTAL SHEET NUMBER
20239-708

17. ☒ The following fees are submitted:
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):
 Neither international preliminary examination fee (37 CFR 1.482)
 nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
 and International Search Report not prepared by the EPO or JPO \$970.00
 International preliminary examination fee (37 CFR 1.482) not paid to
 USPTO but International Search Report prepared by the EPO or JPO \$840.00
 International preliminary examination fee (37 CFR 1.482) not paid to USPTO
 but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00
 International preliminary examination fee paid to USPTO (37 CFR 1.482)
 but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00
 International preliminary examination fee paid to USPTO (37 CFR 1.482)
 and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 840.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☒ 30
 months from the earliest claimed priority date (37 CFR 1.492(e)). \$ 130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	20 - 20 =	0	X \$18.00	\$	0.00
Independent claims	4 - 3 =	1	X \$78.00	\$	78.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	0.00
TOTAL OF ABOVE CALCULATIONS =				\$	1,048.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$	1,048.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	1,048.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$	1,048.00
				Amount to be: refunded	\$
				charged	\$

a. ☒ A check in the amount of \$ 1,048.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 13-0237. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

Carol M. Gruppi
 McCutchen, Doyle, Brown & Enersen, LLP
 Three Embarcadero Center
 San Francisco, CA 94111

Carol M. Gruppi
 SIGNATURE
 Carol M. Gruppi
 NAME
 37,341
 REGISTRATION NUMBER

514 Rec'd PCT/PTO 22 OCT 1999

In The United States Designated Office

In re Application of:

Group Art Unit: To be assigned

Inventor: Klaus Pfeffer

Examiner: To be assigned

Application No: To be assigned

Filed: Herewith

For: TAQMAN™-PCR FOR
THE DETECTION OF
PATHOGENIC E. COLI
STRAINS

PRELIMINARY AMENDMENT

BOX PCT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This preliminary amendment is being filed concurrently with the above identified application which is entering the U. S. national stage from an International Application (PCT 98/EP98/02341) under 35 U.S.C. § 371. Applicant had filed amended claims in PCT 98/EP98/02341 under Article 34 on July 12, 1999 with the International Preliminary Examining Authority (IPEA). A copy of the claims as amended under Article 34 is attached as Exhibit A for the Examiner's reference. The amended claims presented herewith below, are based on the claims as amended under Article 34.

Please enter the following Preliminary Amendment in the above-identified patent application filed **herewith before calculating the claim fees.**

IN THE CLAIMS:

Please amend claims 4, 8, 9, 16, and 17 as follows:

4. (Amended) The method according to claim 1 [claims 1 to 3] wherein a polymerase having additional 5'-3' exonuclease activity is used for the amplification of DNA, and an oligonucleotide probe labelled at the most 5' base with a fluorescent dye and at the most 3' base with a fluorescent quencher dye which hybridises within the target DNA is included in the amplification process; said labelled oligonucleotide probe being susceptible to 5'-3' exonuclease degradation by said polymerase to produce fragments that can be detected by fluorogenic detection methods.

8. (Amended) The method according to claim 4 [claims 4 to 7] wherein the fluorescent reporter dye is 6-carboxy-fluorescein, tetrachloro-6-carboxy-fluorescein, or hexachloro-6-carboxy-fluorescein, and the fluorescent quencher dye is 6-carboxytetramethyl-rhodamine.

9. (Amended) The method according to claim 1 [claims 1 to 8] wherein the amplification process comprises 35 PCR cycles at a MgCl₂ concentration of 5.2 mmol, an annealing temperature of 55 °C and an extension temperature of 65 °C.

16. (Amended) A kit useful for diagnosing an enterobacteria infection in samples derived from a living animal body including a human, by TaqMan™-PCR method, said kit comprising:

(a) a set of primer pair, wherein said primer pair allows differentiation of at least two different groups of pathogenic E. Coli strains by amplification of a virulence factor/toxin gene characteristic for the respective group of the pathogenic E. Coli strains; [according to claims 10 to 12] and

(b) a set of oligonucleotide probes, wherein said set of oligonucleotide probes detect virulence factor/toxin genes of pathogenic E. Coli by TaqMan™-PCR [according to claims 13 to 15].

17. (Amended) The [Use of the] method of claim 1, wherein said method [according to claims 1 to 9] is used to diagnose [for diagnosing] an enterobacteria infection in a sample derived from a living animal body [including a human, or for the detection of an enterobacteria contamination of consumable, such as meat, milk and vegetables].

Please add the following new claims:

18. The method of claim 17, wherein said sample is derived from a human.

19 The method of claim 1, wherein said method is used to detect enterobacteria contamination of a consumable.

20. The method of claim 19, wherein said consumable is selected from the group consisting of meat, milk or vegetable.

Remarks

Based on the Article 34 filed July 12, 1999, claims 1-17 were pending in this application. new claims 18-20 have been added. Support for the newly added claims may be found throughout the specification, such as at page 15, lines 6-10 and page 58, lines 25-28 (originally filed claim 10).


The Commissioner is hereby authorized to charge any fees which may be required in this application to Order No. 20239-706, Deposit Account No. 13-0257. Should no proper payment be enclosed herewith, as by a check being in the wrong account, unsigned, post-date, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 13-0257.

It is respectfully requested that the Examiner contact the undersigned attorney at (650) 849-4902 with any questions regarding the application.

Dated: October 22, 1999

Respectfully submitted,

By:


Carol M. Gruppi
Registration No.: 37,341

McCutchen, Doyle, Brown & Enersen, LLP
Three Embarcadero Center
San Francisco, California 94111
Telephone: (650) 849-4910

Claims as Amended Under Article 34

1. A method for detection of pathogenic enterobacteria in a sample comprising PCR amplification of DNA isolated from said sample using a set of oligonucleotide primer pairs allowing differentiation of at least two groups of pathogenic E. Coli strains by amplification of a virulence factor/toxin gene characteristic for the respective group of the pathogenic E. coli strains.
2. The method according to claim 1 wherein the set of oligonucleotide primer pairs comprises two or more primer pairs selected from
 - a primer pair that hybridises to a gene encoding heat labile toxin, or heat stable toxin for amplification of a DNA sequence characteristic for enterotoxigenic E. coli;
 - a primer pair that hybridises to a gene encoding heat stable toxin for amplification of a DNA sequence characteristic for enteroaggregative E. coli;
 - a primer pair that hybridises to the pCVD432 plasmid for amplification of a DNA sequence characteristic for enteroaggregative E. Coli;
 - a primer pair that hybridises to the inv-plasmid for amplification a DNA sequence contained in enteroinvasive E. Coli;
 - a primer pair that hybridises to the EAF plasmid, or the eae gene for amplification of a DNA sequence characteristic for enteropathogenic E. Coli;
 - a primer pair that hybridises to the genes encoding shiga-like toxin stII or stII for amplification of a DNA sequence characteristic for enterohemorrhagic E. Coli.
3. The method according to claim 2 wherein

the primer pair that hybridises to the gene encoding heat labile toxin characteristic for enterotoxigenic E. Coli is

LT-1: 5' GCG TTA CTA TCC TCT CTA TGT G 3' and
LT-2: 5' AGT TTT CCA TAC TGA TTG CCG C 3';

the primer pair that hybridises to the gene encoding heat stable toxin characteristic for enterotoxigenic E. coli is

ST-1: 5' TCC CTC AGG ATG CTA AAC CAG 3' and
 ST-2a: 5' TCG ATT TAT TCA ACA AAG CAA C 3';

the primer pair that hybridises to the gene encoding heat stable toxin characteristic for enteroaggregative E. Coli is

EASTI-1: 5' AAC TGC TGG GTA TGT GGC TGG 3' and
 EASTI-2: 5' TGC TGA CCT GCC TCT TCC ATG 3';

the primer pair which hybridises to the pCVD432 plasmid is

EA-1: 5' CTG GCG AAA GAC TGT ATC ATT G 3' and
 EA-2: 5' TAA TGT ATA GAA ATC CGC TGT T 3';

the primer pair which hybridises to the inv-plasmid is

EI-1: 5' TTT CTG GAT GGT ATG GTG AGG 3' and
 EI-2: 5' CTT GAA CAT AAG GAA ATA AAC 3';

the primer pair which hybridises to the EAF plasmid is

EP-1: 5' CAG GGT AAA AGA AAG ATG ATA AG 3' and
 EP-2: 5' AAT ATG GGG ACC ATG TAT TAT C 3';

the primer pair which hybridises to the eae gene is

EPeh-1: 5' CCC GCA CCC GGC ACA AGC ATA AG 3' and
 EPeh-2: 5' AGT CTC GCC AGT ATT CGC CAC C 3';

the primer pair which hybridises to the gene encoding shiga-like toxin StII is

StII-1: 5' ATG AAA AAA ACA TTA TTA ATA GC 3' and
 StII-2: 5' TCA CYG AGC TAT TCT GAG TCA AGC 3';

the primer pair which hybridises to the gene encoding shiga-like toxin StII is

StII-1: 5' ATG AAG AAG ATR WTT RTD GCR CYT TTA TTY G 3' and
 StII-2: 5' TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3'

wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T.

4. The method according to claims 1 to 3 wherein a polymerase having additional 5'-3' exonuclease activity is used for the amplification of DNA, and an oligonucleotide probe labelled at the most 5' base with a fluorescent dye and at the most 3' base with a fluorescent quencher dye which hybridises within the target DNA is included in the amplification process; said labelled oligonucleotide probe being susceptible to 5'-3'

exonuclease degradation by said polymerase to produce fragments that can be detected by fluorogenic detection methods.

5. The method according to claim 4 wherein the labelled oligonucleotide probe is specific for the respective virulence factor/toxin gene to be detected.

6. The method according to claim 5 wherein

the labelled oligonucleotide probe is specific for the detection of heat labile toxin characteristic for enterotoxigenic E. Coli;

the labelled oligonucleotide probe is specific for the detection of heat stabile toxin characteristic for enterotoxigenic E. Coli;

the labelled oligonucleotide probe is specific for the detection of heat stabile toxin characteristic for enteroaggregative E. Coli;

the labelled oligonucleotide probe is specific for the detection of pCVD432 plasmid;

the labelled oligonucleotide probe is specific for the detection of the inv-plasmid;

the labelled oligonucleotide probe is specific for the detection of the EAF-plasmid;

the labelled oligonucleotide probe is specific for the detection of the eae gene;

the labelled oligonucleotide probe is specific for the detection of shiga-like toxin StI gene;

the labelled oligonucleotide probe is specific for the detection of shiga-like toxin StII gene.

7. The method according to claim 6 wherein

the labelled oligonucleotide probe for the detection of heat labile toxin characteristic for enterotoxigenic E. Coli is

5' AGC TCC CCA GTC TAT TAC AGA ACT ATG ^{3'};

the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enterotoxigenic E. Coli is

5' ACA TAC GTT ACA GAC ATA ATC AGA ATC AG ^{3'};

the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enteroaggregative E. Coli is

5' ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC ^{3'};

the labelled oligonucleotide probe for the detection of pCVD432 plasmid is

3' CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3';

the labelled oligonucleotide probe for the detection of the inv-plasmid is

5' CAA AAA CAG AAG AAC CTA TGT CTA CCT 3'

the labelled oligonucleotide probe for the detection of the EAF-plasmid is

5' CTT GGA GTG ATC GAA CGG GAT CCA AAT 3';

the labelled oligonucleotide probe for the detection of the eae gene is

5' TAA ACG GGT ATT ATC AAC AGA AAA ATC C 3';

the labelled oligonucleotide probe for the detection of shiga-like toxin SttI gene is

5' TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3';

the labelled oligonucleotide probe for the detection of shiga-like toxin SttII gene is

5' CAG GTA CTG GAT TTG ATT GTG ACA GTC ATT 3'

8. The method according to claims 4 to 7 wherein the fluorescent reporter dye is 6-carboxy-fluorescein, tetrachloro-6-carboxy-fluorescein, or hexachloro-6-carboxy-fluorescein, and the fluorescent quencher dye is 6-carboxytetramethyl-rhodamine.

9. The method according to claims 1 to 8 wherein the amplification process comprises 35 PCR cycles at a MgCl₂ concentration of 5.2 mmol, an annealing temperature of 55 °C and an extension temperature of 65 °C.

10. A set of primer pairs useful for PCR amplification of DNA of pathogenic enterobacteria allowing differentiation of at least two different groups of pathogenic E. Coli strains by amplification of a virulence factor/toxin gene characteristic for the respective group of the pathogenic E. Coli strains.

11. The set of primer pairs according to claim 10 comprising two or more primer pairs selected from

a primer pair that hybridises to a gene encoding heat labile toxin, or heat stable toxin of enterotoxigenic E. Coli;

a primer pair that hybridises to a gene encoding heat stable toxin of enteroaggregative E. Coli;

a primer pair that hybridises to the pCVD432 plasmid of enteroaggregative E. Coli;

a primer pair that hybridises to the inv-plasmid of enteroinvasive E. Coli;

a primer pair that hybridises to the EAF plasmid, or the eae gene of enteropathogenic E. Coli;

a primer pair that hybridises to the gene encoding shiga-like toxin stII or stIII of enterohemorrhagic E. Coli.

12. The set of primer pairs according to claim 11 wherein

the primer pair which hybridises to the gene encoding heat labile toxin of enterotoxigenic E. Coli is

LT-1: 5' GCG TTA CTA TCC TCT CTA TGT G 3' and
LT-2: 5' AGT TTT CCA TAC TGA TTG CCG C 3';

the primer pair which hybridises to the gene encoding heat stabile toxin of enterotoxigenic E. Coli is

ST-1: 5' TCC CTC AGG ATG CTA AAC CAG 3' and
ST-2a: 5' TCG ATT TAT TCA ACA AAG CAA C 3';

the primer pair which hybridises to the gene encoding heat stabile toxin of enteroaggregative E. Coli is

EASTI-1: 5' AAC TGC TGG GTA TGT GGC TGG 3' and
EASTI-2: 5' TGC TGA CCT GCC TCT TCC ATG 3';

the primer pair which hybridises to the pCVD432 plasmid is

EA-1: 5' CTG GCG AAA GAC TGT ATC ATT G 3' and
EA-2: 5' TAA TGT ATA GAA ATC CGC TGT T 3';

the primer pair which hybridises to the inv-plasmid is

EI-1: 5' TTT CTG GAT GGT ATG GTG AGG 3' and
EI-2: 5' CTT GAA CAT AAG GAA ATA AAC 3'

the primer pair which hybridises to the EAF plasmid is

EP-1: 5' CAG GGT AAA AGA AAG ATG ATA AG 3' and
EP-2: 5' AAT ATG GGG ACC ATG TAT TAT C 3';

the primer pair which hybridises to the eae gene is

EPeh-1: 5' CCC GGA CCC GGC ACA AGC ATA AG 3' and
EPeh-2: 5' AGT CTC GCC AGT ATT CGC CAC C 3';

the primer pair which hybridises to the shiga-like toxin *sltI* gene is

SlI-1: 5' ATG AAA AAA ACA TTA TTA ATA GC^{3'} and
SlI-2: 5' TCA CYG AGC TAT TCT GAG TCA AGC^{3'};

the primer pair which hybridises to the shiga-like toxin *sltII* is

SlII-1: 5' ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G^{3'} and
SlII-2: 5' TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC^{3'}

wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T.

13. A set of labelled oligonucleotide probes useful for detection of pathogenic enterobacteria by TaqManTM-PCR being specific for virulence factor/toxin genes of pathogenic *E. Coli* strains.

14. The set of probes according to claim 13 comprising

a labelled oligonucleotide probe specific for the detection of heat labile toxin characteristic for enterotoxigenic *E. Coli*;

a labelled oligonucleotide probe specific for the detection of heat stabile toxin characteristic for enterotoxigenic *E. Coli*;

a labelled oligonucleotide probe specific for the detection of heat stabile toxin characteristic for enteroaggregative *E. Coli*;

a labelled oligonucleotide probe specific for the detection of pCVD432 plasmid;

a labelled oligonucleotide probe specific for the detection of the *inv*-plasmid;

a labelled oligonucleotide probe specific for the detection of the EAF-plasmid;

a labelled oligonucleotide probe specific for the detection of the *eae* gene;

a labelled oligonucleotide probe specific for the detection of shiga-like toxin *SlI* gene;

a labelled oligonucleotide probe specific for the detection of shiga-like toxin *SlII* gene.

15. The set of probes according to claim 14 wherein

the labelled oligonucleotide probe for the detection of heat labile toxin characteristic for enterotoxigenic *E. Coli* is

5' AGC TCC CCA GTC TAT TAC AGA ACT ATG^{3'};

the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enterotoxigenic *E. Coli* is

5' ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3';

the labelled oligonucleotide probe for the detection of heat stable toxin characteristic for enteroaggregative E. Coli is

5' ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3';

the labelled oligonucleotide probe for the detection of pCVD432 plasmid is

5' CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3';

the labelled oligonucleotide probe for the detection of the inv-plasmid is

5' CAA AAA CAG AAG AAC CTA TGT CTA CCT 3'

the labelled oligonucleotide probe for the detection of the EAF-plasmid is

5' CTT GGA GTG ATC GAA CGG GAT CCA AAT 3'

the labelled oligonucleotide probe for the detection of the eae gene is

5' TAA ACG GGT ATT ATC AAC AGA AAA ATC C 3'

the labelled oligonucleotide probe for the detection of shiga-like toxin SttI gene is

5' TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3';

the labelled oligonucleotide probe for the detection of shiga-like toxin SttII gene is

5' CAG GTA CTG GAT TTG ATT GTG ACA GTC ATT 3'

16. A kit useful for diagnosing an enterobacteria infection in samples derived from a living animal body including a human, by TaqMan™-PCR method comprising a set of primer pairs according to claims 10 to 12 and a set of oligonucleotide probes according to claims 13 to 15.

17. Use of the method according to claims 1 to 9 for diagnosing an enterobacteria infection in a sample derived from a living animal body, including a human, or for the detection of an enterobacteria contamination of consumables, such as meat, milk and vegetables.

09/403690

TaqMan™-PCR for the detection of pathogenic E.coli strains

The present invention relates to a rapid, high performance assay for the detection of pathogenic E.coli which is based on TaqMan™ PCR technique, and to specific optimised oligonucleotide primers and labelled oligonucleotide probes useful in the assay.

Background of the Invention

Enterohemorrhagic, shiga-like toxin (slt) producing *Escherichia coli* (EHEC) have recently been recognized as an important human and animal pathogen (1-7). EHEC has been responsible for several food-borne outbreaks (8). The most notable were a multistate outbreak associated with a fast food chain in the western states of the USA with more than 600 individuals affected and 3 deaths in Washington (9), and an epidemic occurrence in Japan with more than 6000 patients and approx. 8 fatal cases (10). Infection with EHEC causes diarrhea, hemorrhagic colitis, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome (HUS) that is characterised by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. HUS ultimately can result in a fatal outcome in affected children and immunocompromised individuals (3,11-17). Recently, in the South-Eastern parts of Germany (Bavaria) an increase of EHEC cases was reported during October 1995 and July 1996 with at least 45 severe infections leading to HUS accompanied by 7 deaths (18). Estimating that approx. 1 out of 15 EHEC infections results in HUS approx. 600 - 700 affected individuals might be assumed.

In most outbreaks reported, consumption of contaminated ground beef has been the source of infection (5,8,19-22), whereas in Japan raddish sprouts are

suspected (10). EHEC has been isolated from cow milk (6,19,23), water (19), chicken, pork, and apple cider (19,24,25), but also human horizontal smear infections have been reported (15). Cattle appear likely to be the reservoir (22,26). Cross contamination, improper handling, and inadequate cooking all contribute to food-borne infections caused by EHEC. EHEC produce Shiga-like toxins (slt), also known as verotoxins or cytotoxins (12,27). A large proportion of EHEC have been found to belong to the serogroup O157:H7, but notably, also a variety of EHEC belonging to other serogroups (O22, O26, O55, O111, O114, O145) have been reported especially in Europe (12,15,28-32).

Besides EHEC, certain other strains of *E.coli* can cause enteritis or gastroenteritis and are grouped in enterotoxigenic strains (ETEC) (33-36), enteropathogenic strains (EPEC) (37), enteroinvasive strains (EIEC) (38,39), and enteroaggregative strains (EaggEC) (40,41). These strains are important pathogens and also pose severe public health problems. The diagnosis of these pathogens is vastly neglected due to the lack of specific and sensitive routine test methods. ETEC synthesize heat labile and/or heat stable enterotoxins that can cause a secretory diarrhea ("traveller's diarrhea") resembling that of *Vibrio cholerae* (36,42,43). Surface attachment of the ETEC organisms to the intestinal epithelial cell is a prerequisite to toxin production. Toxin production is plasmid mediated and most commonly involves *E.coli* serogroups O6, O15, O124, O136, O143, O145, and O147 (32).

EPEC cause diarrheal symptoms primarily in infants (32). Although the pathogenesis is unclear, the epithelial degradation of the gut, and the inflammatory response that are observed in tissue sections may be a consequence due to the adhesive properties of the bacterium. Specific

attachment factors of EPEC are plasmid encoded (EAF=EPEC adherence factor) (37,44). EHEC often contain an adherence factor closely related to EAF that is known as *eae* (EHEC attaching and effacing gene) (45,46). EPEC most often belong to serogroups O6, O8, O25, O111, O119, and O142 (32).

EIEC strains are capable of penetrating and invading the intestinal epithelial cells and produce an inflammatory diarrhea similar to that caused by *Shigella* bacteria (38,47,48). Fecal smears contain blood, mucus and segmented neutrophils. EIEC contain virulence plasmids coding for additional pathogenic factors (48). Serogroups O28, O112, O115, O124, O136, O143, O145, and O147 are most commonly found on EIEC (32).

EaggEC are associated with persistent diarrhea in children and with traveller's diarrhea. EaggEC are characterized by their adherence capacity that leads to aggregation of Hep-2 cells. This effect is associated with the presence of a virulence plasmid (pCVD432). EaggEC are suspected to also produce a heat stable enterotoxin (EAST1) (49-53). They can belong to serogroups O44 and O126 (32).

Conventional detection methods for EHEC encompass enrichment and isolation with selective and/or indicator media such as E.coli broth, lauryl sulfate tryptose 4-methylumbelliferyl-b-acid broth, eosin methylene blue agar, McConkey sorbitol agar, and enterohemolysin agar (28,32,54-59). All of these assays, unfortunately, are indirect and lack the ability to identify EHEC or the other pathogenic *E.coli* strains specifically. Several methods for biochemical identification and immunological detection of EHEC have been put forward (54,60-63), however, it is well recognized that pathogenic *E.coli* strains neither possess nor lack unique fermentation pathways (58,64).

Serotyping is not conclusive since no absolute correlation between serotype and pathogenic *E.coli* group can be established (12,27,32,58,65).

DNA hybridization techniques have been established for experimental research but are not applicable for large scale routine diagnostic procedures (66,67). DNA amplification based assays, using PCR have been reported (68-72). Limitations to these methods include cumbersome post-PCR detection methods (agarose gel electrophoresis, Biotin/ Avidin based ELISA detection systems).

To overcome these problems, a PCR assay which allows the specific determination of virulence factors characteristic for EHEC, ETEC, EPEC, EIEC, and EaggEC that is based on a fluorogenic detection method of PCR amplification has been developed.

This assay exploits the 5' → 3' exonuclease activity of Taq-DNA polymerase (73) to cleave an internal oligonucleotide probe that is covalently conjugated with a fluorescent reporter dye (e.g. 6-carboxy-fluorescein [FAM]; $\lambda_{em} = 518nm$) and a fluorescent quencher dye (6-carboxytetramethyl-rhodamine [TAMRA]; $\lambda_{em} = 582nm$) at the 5' and 3' end, respectively (74,75). Fluorescence from FAM is efficiently quenched by TAMRA on the same, intact probe molecule (76). In the case that cognate PCR amplification occurs, Taq polymerase extends from the specific PCR primer and cleaves the internal, fluorogenic oligonucleotide probe annealed to the template strand. Thus, the reporter dye and the quencher dye get spatially separated. As a consequence of oligonucleotide hydrolysis and physical separation of the reporter and the quencher dyes, a measurable increase in fluorescence

intensity at 518 nm can be observed. PCR cycling leads to exponential amplification of the PCR product and consequently of fluorescence intensity.

TaqMan™-PCR is performed in optical tubes that allow measurements of fluorescence signals without opening the PCR tubes. This dramatically minimizes post-PCR processing time and almost completely eliminates cross-PCR contamination problems. Employing this approach, simultaneous testing of biological materials for the presence of virulence genes of *E.coli* strains and other enterobacteria, harboring virulence genes can be semiautomated and performed within 18 h.

According to the present invention TaqMan™-PCR for the detection of pathogenic *E.coli* is provided, enabling for the first time the specific, rapid and high throughput routine detection of EHEC, ETEC, EPEC, EIEC, and EaggEC and related enterobacteria that harbor these virulence genes in routine bacteriological laboratories.

Object of the Invention

It is an object of the present invention to provide a rapid, high performance assay for the detection and identification of pathogenic *E.coli* in biological samples.

It is a further object of the present invention to provide specific, optimised primers and labelled oligonucleotide probes useful for the amplification of sequences encoding virulence factors/toxins characteristic for pathogenic *E.coli*

Summary of the Invention

5 The invention then, inter alia, comprises the following alone or in combination:

A method for the detection of pathogenic E. coli in a sample comprising PCR amplification of DNA isolated from said sample using a set of
10 oligonucleotide primers specific for virulence factors/toxins of pathogenic E.coli selected from

primers that hybridise to a gene encoding heat labile toxin, or heat stabile toxin for the amplification of a DNA sequence characteristic for
15 enterotoxigenic E. coli;

primers that hybridise to a gene encoding heat stabile toxin for the amplification of a DNA sequence characteristic for enteroaggregative E. coli;

20 primers that hybridise to the pCVD432 plasmid for the amplification of a DNA sequence characteristic for enteroaggregative E.coli;

primers that hybridise to the inv-plasmid for the amplification of a DNA
25 sequence contained in enteroinvasive E.coli;

primers that hybridise to the EAF plasmid, or the eae gene for the amplification of a DNA sequence characteristic for enteropathogenic E.coli;
and/or

30

primers that hybridise to the genes encoding shiga-like toxin stlI or stlII for the amplification of a DNA sequence characteristic for enterohemorrhagic E.coli, followed by detection and identification of the amplified product using conventional methods;

the method as above wherein

the set of primers that hybridise to the gene encoding heat labile toxin characteristic for enterotoxigenic E. coli is

LT-1: 5' GCG TTA CTA TCC TCT CTA TGT G 3' and

LT-2: 5' AGT TTT CCA TAC TGA TTG CCG C 3' ;

the set of primers that hybridise to the gene encoding heat stabile toxin characteristic for enterotoxigenic E. coli is

ST-1: 5' TCC CTC AGG ATG CTA AAC CAG 3' and

ST-2a: 5' TCG ATT TAT TCA ACA AAG CAA C 3' ;

the set of primers that hybridise for the gene encoding heat stabile toxin characteristic for enteroaggregative E. coli is

EASTI-1: 5' AAC TGCT TGG GTA TGT GGC TGG 3' and

EASTI-2: 5' TGC TGA CCT GCC TCT TCC ATG 3' ;

the set of primers which hybridise to the pCVD432 plasmid is

EA-1: 5' CTG GCG AAA GAC TGT ATC ATT G 3' and

EA-2: 5' TAA TGT ATA GAA ATC CGC TGT T 3' ;

the set of primers which hybridise to the inv-plasmid is

EI-1: 5' TTT CTG GAT GGT ATG GTG AGG 3' and

EI-2: 5' CTT GAA CAT AAG GAA ATA AAC 3' ;

the set of primers which hybridise to the EAF plasmid is

EP-1: 5' CAG GGT AAA AGA AAG ATG ATA AG 3' and

EP-2: 5' AAT ATG GGG ACC ATG TAT TAT C 3' ;

the set of primers which hybridise to the eae gene is

EPeh-1: 5' CCC GGA CCC GGC ACA AGC ATA AG 3' and

EPeh-2: 5' AGT CTC GCC AGT ATT CGC CAC C 3' ;

the primers which hybridises to the gene encoding shiga-like toxin StII is

StII-1: 5' ATG AAA AAA ACA TTA TTA ATA GC 3' and

StII-2: 5' TCA CYG AGC TAT TCT GAG TCA AGC 3'; and

the primers which hybridises to the gene encoding shiga-like toxin StIII is

StIII-1: 5' ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3' and

StIII-2: 5' TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3'

wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T;

the method as above wherein a polymerase having additional 5'-3' exonuclease activity is used for the amplification of DNA, and an
5 oligonucleotide probe labelled at the most 5' base with a fluorescent dye and at the most 3' base with a fluorescent quencher dye which hybridises within the target DNA is included in the amplification process; said labelled oligonucleotide probe being susceptible to 5'-3' exonuclease degradation by said polymerase to produce fragments that can be detected
10 by fluorogenic detection methods;

the method as above wherein
15 the labelled oligonucleotide probe for the detection of heat labile toxin characteristic for enterotoxigenic E. coli is

5' AGC TCC CCA GTC TAT TAC AGA ACT ATG 3';

20 the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enterotoxigenic E. coli is

5' ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3';

25 the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enteroaggregative E. coli is

5' ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3';

30 the labelled oligonucleotide probe for the detection of pCVD432 plasmid is

5' CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3';

5 the labelled oligonucleotide probe for the detection of the inv-plasmid is;

5' CAA AAA CAG AAG AAC CTA TGT CTA CCT 3'

the labelled oligonucleotide probe for the detection of the EAF-plasmid is;

10

5' CTT GGA GTG ATC GAA CGG GAT CCA AAT 3';

the labelled oligonucleotide probe for the detection of the eae gene is

15 5' TAA ACG GGT ATT ATC AAC AGA AAA ATCC 3';

the labelled oligonucleotide probe for the detection of shiga-like toxin StII gene is

20 5' TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3'; and

the labelled oligonucleotide probe for the detection of shiga-like toxin StII gene is

25 5' CAG GTA CTG GAT TTG ATT GTG ACA GTC ATT 3';

the method as above wherein the fluorescent reporter dye is 6-carboxy-fluorescein, tetrachloro-6-carboxy-fluorescein, or hexachloro-6-carboxy-fluorescein, and the fluorescent quencher dye is 6-carboxytetramethyl-rhodamine;

30

the method as above wherein the PCR amplification process consists of 35 PCR cycles at a $MgCl_2$ concentration of 5.2 mmol, an annealing temperature of 55 °C and an extension temperature of 65 °C;

a set of primers useful for PCR amplification of DNA specific for virulence factors/toxins of pathogenic *E. coli* selected from:

a set of primers that hybridise to a gene encoding heat labile toxin, or heat stabile toxin of enterotoxigenic *E. coli*;

a set of primers that hybridise to a gene encoding heat stabile toxin of enteroaggregative *E. coli*;

a set of primers that hybridise to the pCVD432 plasmid of enteroaggregative *E. coli*;

a set of primers that hybridise to the *inv*-plasmid of enteroinvasive *E. coli*;

a set of primers that hybridise to the EAF plasmid, or the *eae* gene of enteropathogenic *E. coli*; and

a set of primers that hybridise to the gene encoding shiga-like toxin *stxI* or *stxII* of enterohemorrhagic *E. coli*;

the set of primers as above wherein

the set of primers which hybridise to the gene encoding heat labile toxin of

enterotoxigenic *E. coli* is

- 5 LT-1: 5' GCG TTA CTA TCC TCT CTA TGT G³ and
LT-2: 5' AGT TTT CCA TAC TGA TTG CCG C³ ;

the set of primers which hybridise to the gene encoding heat stabile toxin
of enterotoxigenic *E. coli* is

- 10 ST-1: 5' TCC CTC AGG ATG CTA AAC CAG³ and
ST-2a: 5' TCG ATT TAT TCA ACA AAG CAA C³ ;

the set of primers which hybridise to the gene encoding heat stabile toxin
of enteroaggregative *E. coli* is

- 15 EASTI-1: 5' AAC TGCTGG GTA TGT GGC TGG³ and
EASTI-2: 5' TGC TGA CCT GCC TCT TCC ATG³ ;

20 the set of primers which hybridise to the pCVD432 plasmid is

- EA-1: 5' CTG GCG AAA GAC TGT ATC ATT G³ and
EA-2: 5' TAA TGT ATA GAA ATCCGC TGT T³ ;

25 the set of primers which hybridise to the inv-plasmid is

- EI-1: 5' TTT CTG GAT GGT ATG GTG AGG³ and
EI-2: 5' CTT GAA CAT AAG GAA ATA AAC³ ;

30 the set of primers which hybridise to the EAF plasmid is

EP-1: 5' CAG GGT AAA AGA AAG ATG ATA AG 3' and

EP-2: 5' AAT ATG GGG ACC ATG TAT TAT C 3' ;

5

the set of primers which hybridise to the eae gene is

EPeh-1: 5' CCC GGA CCC GGC ACA AGC ATA AG 3' and

EPeh-2: 5' AGT CTC GCC AGT ATT CGC CAC C 3' ;

10

the set of primers which hybridise to the shiga-like toxin sltI gene is

Sltl-1: 5' ATG AAA AAA ACA TTA TTA ATA GC 3' and

Sltl-2: 5' TCA CYG AGC TAT TCT GAG TCA AGC 3' ;

15

and

the set of primers which hybridise to the shiga-like toxin sltII is

20 SltlI-1: 5' ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3' and

SltlI-2: 5' TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3'

wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T;

25

the set of primers as above which in addition to the primers for amplification of target DNA comprise a labelled oligonucleotide probe which is labelled with a fluorescent reporter dye, such as 6-carboxy-fluorescein, tetrachloro-6-carboxy-fluorescein, hexachloro-6-carboxy-fluorescein, at the most 5' base and a fluorescent quencher dye, such as 6-

30

carboxytetramethyl-rhodamine, at the most 3' base, and have a nucleotide sequence selected from

5

5' AGC TCC CCA GTC TAT TAC AGA ACT ATG 3'

which hybridises to a gene encoding heat labile toxin of enterotoxigenic *E. coli*;

10

5' ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3'

which hybridises to a gene encoding heat stabile toxin of enterotoxigenic *E. coli*;

15

5' ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3'

which hybridises to a gene encoding heat stabile toxin of enteroaggregative *E. coli*;

20

5' CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3'

which hybridises to the pCVD432 plasmid;

5' CAA AAA CAG AAG AAC CTA TGT CTA CCT 3'

which hybridises to the inv-plasmid;

25

5' CTT GGA GTG ATC GAA CGG GAT CCA AAT 3'

which hybridises to the EAF plasmid;

5' TAA ACG GGT ATT ATC AAC AGA AAA ATCC 3'

which hybridises to the eae gene;

30

5' TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3'

which hybridises to the shiga-like toxin *StxI* gene; and

5' CAG GTA CTG GAT TTG ATT GTG ACA GTC ATT 3'

which hybridises to the shiga-like toxin StII gene;

the use of the method as above for diagnosing an *E.coli* infection of a living animal body, including a human, or for the detection of *E. coli* contamination of consumables, such as meat, milk and vegetables.

The Invention

Conventional methods used to detect PCR amplification are laboursome, employ potentially carcinogenic substances (ethidium bromide gel electrophoresis), and are not suited as a routine assay method in the microbiological routine laboratory (68-72). This poses a serious problem, especially when potential pathogenic bacteria cannot be differentiated from facultative pathogenic or apathogenic ones due to characteristic biochemical, serological and/or morphological criteria. Thus, specific nucleic acid-based diagnostic methods that directly detect virulence factors or toxins harbored by these species are mandatory. This is in principal the case for the diagnosis of pathogenic *E.coli* bacteria. Biochemical properties of EHEC, EPEC, EIEC, ETEC, and EaggEC are not unique and cannot be used for setting them apart from other *E.coli* strains (54,60-62). Furthermore, virulence plasmids of *E.coli* can be found in other enterobacteria as well (38,48,83,88,89). Because of the diverse serological makeup, identification of pathogenic *E.coli* by serotyping is also not an accurate means of identification (12,15,28-32). Classical colony hybridization assays with probes specific for characteristic virulence factor and/or toxin genes are laborous and timeconsuming (66,67). Classical PCR methods require

various post-PCR steps in order to verify whether specific amplification of a target gene has occurred (68-72). The TaqManTM-PCR detection system (74,75,90) enables the rapid, specific, sensitive, and high-throughput diagnosis for differentiation of pathogenic *E.coli* strains from other strains of *E.coli*. The assay has the ability to quantify the initial target sequence. Since PCR-reaction tubes have not to be opened after PCR cycling, the potential danger of cross-PCR contamination is almost negligible. The scanning time of 96 samples is approximately 8 min, and calculation of test results can be automated with a commercially available spread sheet program. Thus, overall post-PCR processing time is cut to a minimum.

The TaqManTM-system relies on standard PCR technique with the addition of a specific internal fluorogenic oligonucleotide probe. The combination of conventional PCR with the Taq polymerase-dependent degradation of an internally hybridized oligonucleotide probe confers also specificity to this detection method, since it is highly unlikely that unspecific PCR amplification will yield positive fluorescence signals. Some rules for choosing the fluorogenic probes have to be obeyed (74,75). Critical are the length of the probe, the location of reporter and quencher dyes and the absence of a guanosine at the 5'-end (74). Also, the distance of the probe from one of the specific PCR primers is important. This is due to the fact that the probe has to stay annealed to the template strand in order to be cleaved by Taq polymerase. Since annealing depends, at least partially, on the T_m of the probe, probes should be designed to have a higher T_m as the primers. According to the present invention this was solved (except for *stII*) by designing probes that were 3 to 6 bp longer than the specific primers. PCR amplification includes extension of the target sequence after annealing of the primers and the T_m of the extended primers increases. For

the fluorogenic oligonucleotide probe, where the 3'- end is capped in order to avoid elongation, the T_m remains constant, making it more likely that the probe dissociates before degradation by Taq polymerase. Oligonucleotide probe degradation can be optimized by spatial proximity of the fluorogenic probe and the primer. By moving the probe for sltI from 121 bp to 9 bp close to the primer, a significant improvement in ΔRQ values could be obtained. A second strategy of optimization of TaqManTM-PCR is to perform PCR elongation at 65°C, where it is also less likely that the probe dissociates from the template strand before Taq polymerase reaches and hydrolyzes it. Values for ΔRQ can thus again be increased about 1.2 to 1.5 fold. The increase of ΔRQ values might be due to the ratio of annealed oligonucleotide probe reached by Taq polymerase or to an increased processivity of Taq polymerase.

The concentration of fluorogenic probes influences the accuracy of TaqManTM-results. When the probe concentrations were > 50 pmol / PCR reaction only a relatively small fraction was hydrolysed by Taq polymerase. The ratio of undegraded probe to degraded probe remains high and the fluorescence emission of the unquenched reporter dye does not significantly increase in relation to the fluorescence intensity of the reporter dye still close to the quencher. Thus, at high probe concentrations, ΔRQ values are lower than with intermediate probe concentrations (10 - 20 pmol). When the probe concentration is too low, ΔRQ values are increased, however, variability of PCR results is increased, since probably small errors in pipeting or minimal differences between PCR reactions become critical. Optimal probe concentration that yielded smallest variabilities and highest RQ values were found at a probe concentration of 20 pmol.

Since TaqMan™-PCR uses an internal oligonucleotide probe for detection of template amplification, specific primers and probes can be amply designed. The design of primer and probe sequences is especially important, when nucleotide sequence variants of a given gene exist. This is the case for *sltI* and *sltII*. For *sltI*, all published sequences were aligned and primers and probes were designed to bind to conserved regions of all three variants. For *sltII*, only one region of the published genes was conserved, thus this region was chosen for the fluorogenic oligonucleotide probe. The primers for amplification of *sltII* were designed to contain all possible nucleotide sequences at the ambiguous positions of the published *sltII* variants (degenerate primer approach) (79-83). By employing degenerate primers, it is possible to detect all published variants in one single PCR reaction.

The isolation method for template DNA affects the performance of the PCR. Two methods, that are suited as rapid purification steps for routine applications, namely boiling prep or spin prep were compared. Boiling preps may still contain some bacterial components that can affect PCR reactions, however, it is extremely fast. The spin prep method involves isolation steps that serve to purify DNA from potentially negatively influencing materials. ΔRQ values and sensitivity of TaqMan™-PCR for virulence genes from enterobacteria was not found significantly increased as compared to boiling preps when template DNA was prepared by spin prep method.

The overall sensitivity of TaqMan-PCR for all primer/probe combinations was comparable to visual scoring of PCR products by detection with ethidium bromide stained agarose gel electrophoresis. Under optimized

conditions, as few as 10^3 cfu slt1+ EHEC could be detected among 10^7 non-pathogenic *E.coli* per PCR reaction.

5

The use of immunomagnetic detection methods for *E. coli* O157 (54,91) has been put forward as a means to improve sensitivity of EHEC diagnostics by enrichment of this serogroup since the first slt producing strains were found to be O157:H7 positive (1,2). However, it is obvious that EHEC that are O157 antigen negative will be missed by this method. It became clear during serotyping studies of recent EHEC isolates that the number of O157+ EHEC now is small as compared to non-O157 EHEC (12,15,28,29,31). In a recent study, conducted in Southern Germany only 2 of 13 isolates were O157 positive (92). Immunomagnetic detection methods for other O serotypes are currently not available. Also, other enterobacteria such as *Citrobacter sp.* (83) and *Enterobacter sp.* (89) that can harbor shiga like toxins would be missed in the case of biased enrichment procedures previous to analysis of virulence genes. Thus, TaqMan™-based PCR that is designed for detection of virulence genes in all enterobacteria appears to be superior.

10
15
20

The infectious agents of a large proportion of diarrheal diseases is not known. Routine screening for bacterial pathogens in the gastrointestinal tract encompasses *Salmonella sp.*, *Shigella sp.*, *S. aureus*, *Campylobacter sp.*, *Vibrio sp.*, *Yersinia sp.*, and *C. difficile* (32). It is well recognized that pathogenic *E.coli* such as ETEC, EHEC, EIEC, and EaggEC are important pathogens of the lower gastrointestinal tract and therefore might significantly contribute to the number of diarrheal infections (32). However, no routine bacteriological diagnostic procedures for these bacteria are performed, and, moreover, in most cases these pathogenic *E. coli* are misdiagnosed under the category of non-pathogenic "commensal

25
30

flora". In order to address this problem a set of specific primers and
fluorogenic probes were developed and optimized for TaqMan™-based
5 detection of virulence factors harbored by these bacteria (Tables 2 and 3).
Arranging patient samples, positive and no-template controls of all 8 tested
virulence genes in a standard 96 well microtiter format, a turnaround time
from preparation of sample DNA to fluorescence measurement of under 5
hours can be achieved. Thus, the TaqMan™-based assay for pathogenic
10 E.coli provides an ultrarapid means of diagnosis of these bacteria. While
being accurate, sensitive and specific, this assay requires minimal post-PCR
processing time compared to conventional methods. When TaqMan™ PCR
is performed in optical tubes also the danger of cross-contamination of PCR
reactions with amplified products is reduced to a minimum. Detection of
15 virulence plasmids harbored by pathogenic enterobacteria might prove the
potential of these bacteria to cause disease in the host. It is not clear
whether enterobacteria that contain toxin genes or attachment factors do
also always express them outside the host. This might be an explanation
why ELISA tests for shiga like toxins might be negative in a number of HUS
20 cases where *stxI* and/or *stxII* containing EHECs can be detected by nucleic
acid based methods.

The TaqMan™-assay according to the invention for detection of pathogenic
E.coli was then tested in a routine diagnostic setting for the examination of
25 stool samples obtained from children with diarrhea within a defined
geographic area (Southern Bavaria) during a 7 month period. Results
obtained by TaqMan™-PCR were compared to the standard detection
method for PCR products (electrophoresis of ethidium stained agarose
gels). 100 stool samples were analysed (Table 4). 22% of samples were
30 found to test positive for one or more virulence factors. There were 2 cases

of EHEC, 5 ETEC, 8 EaggEC, 1 EIEC, and 16 EPEC. This means that 1/5 of children with diarrhea probably suffered from diarrhea caused by pathogenic *E.coli*. These numbers are far higher than these for all other groups of routinely screened bacterial gastrointestinal tract pathogens. Only 2 cases of salmonella and no campylobacter were observed within this group.

Interestingly, the two children diagnosed with EHEC were severely sick, one suffered from hemorrhagic colitis, the other developed HUS and had to be treated in a critical care unit.

Collectively, these investigations show that a large proportion of diarrheal diseases in children and also in adults are associated with pathogenic *E.coli* that are falsely diagnosed as commensal flora in standard microbiological procedures. The TaqMan™-methodology according to the invention for the first time enables the direct, fast, specific, and sensitive detection of these important pathogens. Moreover, virulence genes detected with this approach are not confined to *E.coli*, they also can be freely transmitted to other enterobacteria. Detection of the virulence genes within these bacteria would also be covered by the herein described TaqMan™-PCR. The assay requires only minimal post-PCR detection time, can thus be performed under 18 hours, and abolishes PCR-cross contamination problems.

According to the present invention *E.coli* virulence factor / toxin genes were used as targets for PCR amplification. PCR primers and fluorogenic probes were designed on the basis of published sequences. Eight different primer and probe sets for detection of pathogenic groups of *E.coli* and related enterobacteria were specifically chosen, see table 1.

Primer sequences and their locations with GenBank accessions are detailed in Table 2. Detection of EHEC *sltI* is based on consensus primer and probe sequences after alignment of *sltI* homologous genes (Genbank accessions Z36899, Z36900, and Z36901) (77,78). Detection of *sltII* variants is based on published sequences of homologous genes (Genbank accessions M76738, Z37725, L11079, X67515, M59432, M29153, M36727, and M21534) (79-83). For amplification of *sltII*, degenerate primer sets proved optimal. Diagnosis of ETEC is based on amplification of either heat labile (LT) (84) or heat stable toxin (ST) (36), EaggEC on pCVD432 plasmid sequences (40,50), EIEC on *inv*-plasmid sequences (38,48), EPEC on *E.coli* attaching and effacing gene (EAF plasmid) (37,85) or *E.coli* gene for EHEC attaching and effacing protein (*eae*) (86). PCR control amplification for integrity of DNA preparations was performed using primers specific for the *E.coli* *parC* gene (topoisomerase IV, Genbank accession M58408) (87).

Oligonucleotide probes and their Genbank Ref. are shown in table 3. Oligonucleotide probes were designed (if possible) with a GC-content of 40-60%, no G-nucleotide at the 5'-end, length of probes was 27 to 30 bp. Probes were covalently conjugated with a fluorescent reporter dye (e.g. 6-carboxy-fluorescein [FAM]; $\lambda_{em} = 518nm$) and a fluorescent quencher dye (6-carboxytetram-ethyl-rhodamine [TAMRA]; $\lambda_{em} = 582nm$) at the most 5' and most 3' base, respectively. All primers and probes were obtained from Perkin Elmer, Germany.

TaqMan™-PCR was optimized by isolation of DNA from *E.coli* control strains harboring genes for LT, ST, *inv*-plasmid, pCVD342, EAF, *eae*, *sltI* and *sltII* (see Table 1). $MgCl_2$ concentrations were adjusted for maximum PCR

product yields (as verified by agarose gel electrophoresis) and RQ values
($RQ = \frac{\text{FAM fluorescence intensity}}{\text{TAMRA fluorescence intensity}}$) with the above
5 mentioned pathogenic *E.coli* control strains. Optimum PCR reactions for all
primer / fluorogenic probes used were obtained at a MgCl_2 concentration of
5.2 mmol, 35 PCR cycles, an annealing temperature of 55°C and an
extension temperature of 65°C. Extension at 65°C was found to yield higher
RQ values, probably due to a lower rate of template/fluorogenic probe
10 dissociation before degradation by Taq-polymerase.

The *E.coli* *sltI* gene was used as a target sequence for establishment of PCR
and analysing different locations of probes relative to the PCR primers.
Primers were designed to anneal in conserved regions of the *sltI* genes (see
15 above). Two probes, *sltI*-N0 located 132 bp upstream of one primer and *sltI*-
N1, placed at a 21 bp distance from the primer were compared. RQ values
achieved with probe *sltI*-N1 ($RQ_m = 6.3800$) were reproducibly found higher
than RQ values generated with probe *sltI*-N0 ($RQ_m = 0.9620$) at equal
template concentrations of the *E.coli* *sltI* control DNA. Generally, also
20 probes specific for other target genes that were located close (4 to 20 bp) to
one of the two PCR primers yielded consistently higher RQ values than
probes that were placed at a greater distance from the primers.

The influence of DNA preparation on the performance of TaqMan™-PCR
25 was tested, since it has been reported that crude bacterial lysates can contain
inhibiting factors that might interfere with PCR performance. Therefore,
bacteria were collected after overnight growth on McConkey plates. DNA
was prepared by boiling of bacteria inoculated in 0.9% NaCl solution or by
isolation of genomic DNA with a commercial spin prep procedure (see the
30 example, material and methods). The RQ values and sensitivity of

TaqManTM-PCR did not differ when the two preparation methods were compared. The RQ values obtained for PCR amplifications from DNA
5 derived from 10⁵ sltI or sltII containing EHEC prepared by boiling or by spin prep comparable.

The TaqManTM-PCR method relies on the detection of free reporter dye (FAM) that is released from the probe after hydrolysis. Thus, probe
10 concentration should also have an effect on the assay performance by affecting the fraction of the probe that is degraded during PCR cycling. Probe concentrations were titrated in the range of 100 pmol to 0.1 pmol and Δ RQ values were determined. Optimal probe concentrations varied in
15 between 10 pmol and 20 pmol depending on the target gene that was amplified.

For testing sensitivity of TaqMan-PCR, EHEC containing either sltI or sltII were diluted in a suspension containing E.coli strain ATCC11775 at 10⁷ cfu at log step dilutions. PCR was performed under optimized conditions and
20 results from ethidium-bromide stained agarose gels were compared to TaqManTM results. Minimum detection limits of a sltI containing EHEC strain was 10³ cfu within 10⁷. For sltII the detection limit was found at 10^{3.5} cfu in 10⁷ enterobacteria. Both methods, detection of PCR products by agarose gel electrophoresis and measurement of fluorescence signals by the
25 TaqMan method yielded comparable results, i.e. that at Δ RQ values above Δ RQ_{threshold} PCR product bands were visible in agarose gels, whereas at Δ RQ values around Δ RQ_{threshold} also in agarose gels PCR products were below the detection limit. After optimizing detection tests for all virulence factors/toxins, TaqManTM-PCR was set up for routine testing of biological
30

specimen for the presence of pathogenic *E.coli* bacteria. Results of TaqManTM-PCR were compared to agarose gel electrophoresis.

The following example will illustrate the invention further. It is, however, not to be construed as limiting.

Example

1. Prevalence of pathogenic *E.coli* in stool specimens from children with diarrhea was tested using the method according to the invention.

In order to verify TaqManTM-PCR performance and to test for the occurrence of pathogenic *E.coli* screening of 100 stool specimens from children of age 0 to 10 years with the clinical symptoms of diarrhea was undertaken. The materials and methods used in the test are described in more detail below under item 2.

Collection of specimen took place from June to October 1996. All samples in this study were derived from the area of Southern Bavaria. Stool specimen were plated on McConkey agar, incubated overnight and enterobacteria were collected. DNA was isolated and used as template in PCR reactions containing specific primers and fluorogenic probes for *sltI*, *sltII*, LT, ST, EAF-plasmid, *eae*-gene, *inv*-plasmid, and pCVD432. For verification of the integrity of DNA from individual preparations a control PCR reaction was set up, containing primers and an internal fluorogenic probe for amplification of the *parC* gene of *E.coli*. As a positive assay control, one PCR reaction was performed within each assay, where DNA from a positive

control strain for the respective virulence factor/toxin was present. Applying this method reliable, specific and sensitive detection of all target genes could be achieved. Systematic analysis of 100 stool specimen derived from children suffering from diarrhea yielded 22 samples where one, two or three of the virulence factors/toxins of pathogenic *E.coli* could be detected. In detail, 2 patients harbored EHEC (one with hemorrhagic colitis and one developed HUS). 3 patients tested positive for ETEC, 16 for EPEC, 1 for EIEC, and 8 for EaggEC (see Table 4). The patient suffering from hemorrhagic colitis tested positive for *sltI* and *eae*, the patient developing HUS tested positive for *sltI*, *sltII* and *eae*. One patient simultaneously harbored ETEC (LT+,ST+), EPEC (*eae*+), and EaggEC (pCVD342+), one patient tested positive for EIEC (inv+) and EaggEC (pCVD342+), two stool specimen contained EPEC (*eae*+) and EaggEC (pCVD342).

Enterobacteria from the two patients with EHEC were hybridized with *sltI* and *sltII* gene probes for testing accuracy and specificity of TaqMan™-PCR. In the case of patient one, where TaqMan™-PCR was positive for *sltI*, only colonies hybridizing with *sltI* could be found. Colonies of patient two, where TaqMan™-PCR was positive for *sltI* and *sltII*, hybridized with probes for *sltI* and *sltII*. Positive colonies were picked and biochemically typed as *E.coli*.

Antibiotic susceptibility testing revealed that EHEC strains were sensitive to broad spectrum penicillins, cephalosporins and gyrase inhibitors.

2. Materials and Methods

a) Bacterial strains, media, culture and DNA preparation: A number of EHEC, ETEC, EPEC, EIEC, and EaggEC *E.coli* strains were used as controls

for accurate PCR amplification and were kindly provided by H. Karch, Würzburg, Germany and H. Beutin, Berlin, Germany (see Table 1) As a strain not harboring these virulence genes *E.coli* ATCC 11775 was used. For TaqMan™-PCR optimization, positive control strains were grown on McConkey agar (Becton Dickinson, Germany) at 37°C. After overnight culture, bacteria were collected and resuspended in 0.9% NaCl solution. Turbidity was adjusted to McFarland 0.5. DNA was either prepared by boiling (95°C, 10 min) or isolated using QiaAmp tissue kit spin prep columns (Qiagen, Germany). 10 µl of DNA suspension was used for PCR. Detection of pathogenic *E.coli* strains from stool specimen of humans or cows was performed after spreading an appropriate amount of stool on McConkey plates. After overnight culture all bacterial colonies from the surface of the McConkey plates were collected and processed as detailed above.

b) PCR-cycling: PCR reactions were set up in 70µl final volume in thin-walled 0.2ml "optical PCR-tubes" (Perkin Elmer, Germany). The reaction mix contained: 10µl of bacterial lysate, 5.25 µl 25 mmol MgCl₂, 7 µl 10x PCR buffer, 40 pmol primers, 20 pmol specific fluorogenic probe, 150 µM of each dATP, dTTP, dGTP, dCTP (Perkin Elmer), 1 U AmpliTaq-Polymerase (Perkin Elmer). A Perkin Elmer model 9600 thermal cycler was used for PCR cycling. Initial denaturation of bacterial DNA was performed by heating for 5 min to 94°C. All cycles included a denaturation step for 15 sec at 94°C, annealing for 1 min 30 sec at 55°C, and extension for 1 min 30 sec at 65°C. 35 cycles were performed.

c) Post-PCR processing: After completion of cycling, the fluorescence intensities of the reporter dye, FAM, and the quencher dye, TAMRA, were

determined using a Perkin Elmer LS50B luminiscence spectrophotometer equipped with a plate reader and modified for fluorescence measurements of PCR reactions in optical tubes. ΔRQ values were calculated as described in (74). A $\Delta RQ_{\text{threshold}}$ value was calculated on the basis of a 99% confidence interval above the mean of the triplicate no template controls ($\Delta RQ_{\text{threshold}} = 6,95 \times \text{std}_{\text{mean of no template controls}}$). PCR reactions were scored positive if $\Delta RQ_{\text{sample}} > \Delta RQ_{\text{threshold}}$ was given. For verification of the sensitivity of TaqManTM-measurements, PCR products were subjected to agarose gel electrophoresis. 15 μl of sample were loaded with 2 μl sample buffer. PCR products were separated in 2% agarose gels containing ethidium bromide at 100V for 35 min. DNA was visualized under UV light and a digital image file was obtained using the Eagle EyeII System (Stratagene).

d) Verification of PCR amplicates: PCR products obtained from templates of respective positive control strains were directly subcloned into the TA cloning vector (Invitrogen, Germany) for verification of specificity of PCR amplification. After transfection (CaCl₂-method) of DH5 α bacteria with the ligation products, plasmid containing bacteria were selected on ampicillin (Sigma, Germany) containing LB plates. Plasmid DNA was purified with Qiagen DNA purification columns (Quiagen, Germany). Inserts were PCR-cycle sequenced employing dideoxy-nucleotides conjugated to 4 dyes (DNA Dye terminator cycle sequencing kit, Perkin Elmer, Germany). Sequences were obtained with an Applied Biosystems model 373A (Applied Biosystems, Germany). Insert sequences were aligned to published sequences as referenced in Table 1 using the McDNAsis programme (Appligene, Great Britain). Sequence comparisons verified that the PCR products were identical to the respective virulence factors or toxins.

e) Sensitivity of TaqMan™ technique: For determination of the sensitivity of the TaqMan method, serial log-step dilutions of positive control strains were performed in a solution containing 10^7 cfu of *E.coli* reference strain ATCC 11775 DNA was either prepared by the boiling method (see above) or purified using spin prep columns designed for isolation of genomic bacterial DNA (Qiagen, Germany). Purification was according to the protocol of the manufacturer. The detection limit for *sltI* containing strains was determined with 10^3 cfu among 10^7 *E.coli* and for *sltII* containing strains as $10^{3.5}$ among 10^7 .

f) Colony hybridisation and isolation of EHEC bacteria: EHEC bacterial strains and stool samples from patients testing positive in *sltI* or *sltII* TaqMan™-PCR were subjected to colony hybridisation. Briefly, bacteria were plated on McConkey agar plates such that single colonies could be seen. Bacteria were blotted on nylon membranes (Genescreen Plus, NEN, Germany), cracked (1% SDS), denatured (0.5M NaOH, 1.5M NaCl), neutralized (1M TRIS, 1.5M NaCl), and washed (20xSSC). Membranes were baked at 80°C for 2 hours. DNA probes specific for *sltI* or *sltII* were labelled with fluorescein (Gene-Images random prime labelling module, Amersham, Germany). Afterwards, filters were hybridized with labelled probes. Hybridization was verified by non-radioactive detection system employing anti-FITC peroxidase mAb and ECL detection module (Gene-Images CDP-Star detection module, Amersham, Germany). Bacterial colonies hybridizing with the probe and non-hybridizing colonies were picked, verified by TaqMan-PCR and tested for antibiotic susceptibility.

Antibiotic susceptibility testing. EHEC and non-EHEC *E.coli* were picked from McConkey plates after testing for *sltI* or *sltII* or both toxin genes in colony hybridization. and MIC testing was performed according to NCCLS guidelines for enterobacteria.

Group	Strain number	Serotype	Virulence factor / toxin
EHEC	1193/89	O157:H-	sltI, <i>eae</i>
	3574/92	O157:H7	sltII, <i>eae</i>
	A9167C	O157:H7	sltI,sltIIc, <i>eae</i>
	5769/87	O157:H7	sltI, sltII, <i>eae</i>
	427/89	O157:H-	sltI,sltIIc, <i>eae</i>
	1249/87	O157:H7	sltII, sltIIc, <i>eae</i>
ETEC	147/1	O128:H-	ST
	164/82	O148:H28	LT
EPEC	111/87	O111	EAF, <i>eae</i>
	12810	O114:H2	EAF, <i>eae</i>
EIEC	76-5	O143	<i>inv</i> -plasmid
	12860	O124	<i>inv</i> -plasmid
EaggEC			pCVD432 plasmid
control	ATCC 11775		--

Table 1: E.coli strains - virulence factors/toxins

Group	Virulence factor / toxin	Primer	Sequence (5'→3')	location of primer	Size of PCR product	Gen-bankRef.	Ref.
ETEC	LT	LT-1	gcg tta cta tcc tct cta tgt g	874-895 1213-1192	339	S60731	(84)
		LT-2	agt ttt cca tac tga ttg ccg c				
	ST	ST-1	tcc ctc agg atg cta aac cag	100-120 360-339	260	M34916	(36)
		ST-2a	tcg att tat tca aca aag caa c				
EaggEC	pCVD432 plasmid	EA-1	ctg gcg aaa gac tgt atc att g	66-87 695-674	629	X81423	(40,50)
		EA-2	taa tgt ata gaa atc cgc tgt t				
EIEC	inv-plasmid	EI-1	ttt ctg gat ggt atg gtg agg	17786-17806 18089-18069	303	D50601 emb	(38,48)
		EI-2	ctt gaa cat aag gaa ata aac				
EPEC	EAF plasmid	EP-1	cag ggt aaa aga aag atg ata ag	546-568 944-923	398	X76137	(37,85)
		EP-2	aat atg ggg acc atg tat tat c				
	eae	EPeh-1	ccc gga ccc ggc aca agc ata ag	91-113 963-942	872	Z11541	(86)
		EPeh-2	agt ctc gcc agt att cgc cac c				
EHEC	sltI	sltI-1	atg aaa aaa aca tta tta ata gc	1113-1135 1400-1376	287	Z36899	(77,78)
		sltI-2	tca cyg agc tat tct gag tca acg				
	sltII	sltII-1	atg aag aag atr wtt rtd gcr	1148-1178 1413-1385	265	L11079	(79-83)
		sltII-2	gyt tta tty g tca gtc atw att aaa ctk cac yts				

			rgc aaa kcc				
control	parC	par-1	aac ctg ttc agc gcc gca ttg	141- 161 401-381	260	M58408	(87)
		par-2	aca acc ggg att cgg tgt aac				

Table 2: Primers for detection of pathogenic *E.coli*. W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T.

Group	virulenc e factor / toxin	Probe for Taqman TM (FAM-5' → 3'-TAMRA)	bp	Gen- bank Ref.	Ref.
ETEC	LT	agc tcc cca gtc tat tac aga act atg	903- 929	S60731	(84)
	ST	aca tac gtt aca gac ata atc aga atc ag	334- 306	M34916	(36)
EaggEC	pCVD43 2 plasmid	ctc ttt taa ctt atg ata tgt aat gtc tgg	668- 639	X81423	(40,50)
EIEC	inv plasmid	caa aaa cag aag aac cta tgt cta cct	18063- 18037	D50601 emb	(38,48)
EPEC	EAF plasmid	ctt gga gtg atc gaa cgg gat cca aat	575- 601	X76137	(37,85)
	eae	taa acg ggt att atc acc aga aaa atc c	935- 908	Z11541	(86)
EHEC	sltI	tcg ctg aat ccc cct cca tta tga cag gca	1367- 1338	Z36899	(77,78)
	sltII	cag gta ctg gat ttg att gtg aca gtc att	1371- 1342	L11079	(79-83)
control	parC	atg tct gaa ctg ggc ctg aat gcc agc	169- 199	M58408	(87)
		gcc			

Table 3: TaqManTM-probes used for detection of pathogenic *E.coli*

Group	virulence factor / toxin	TaqMan: number of positive isolates	Agar gel electrophoresis: number of positive isolates	pathogenic group
ETEC	LT	2	2	5
	ST	3	3	
EaggEC	60 kb plasmid	8	8	8
EIEC	inv plasmid	1	1	1
EPEC	EAF plasmid	1	1	16
	eae	15	15	
EHEC	sttI	2	2	2
	sttII	1	1	
control	parC	100	100	

Table 4: Frequency of pathogenic *E.coli* in stool samples of children with diarrhea (n=100)

References:

- 5 1. Centers for Disease Control. 1982. Isolation of *E. coli* O157:H7 from sporadic cases of hemorrhagic colitis - United States. *MMWR. Morb. Mortal. Wkly. Rep.* 31:580, 585.
2. Karmali, M. A., M. Petric, C. Lim, P. C. Fleming, and B. T. Steele. 1983. *Escherichia coli* cytotoxin, haemolytic-uraemic syndrome, and
10 haemorrhagic colitis [letter]. *Lancet* 2:1299.
3. Karmali, M. A., M. Petric, C. Lim, and P. C. Fleming. 1985. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing *Escherichia coli*. *J. Infect. Dis.* 151:775.
15
4. Riley, L. W., R. S. Remis, S. D. Helgerson, H. B. McGee, J. G. Wells, B. R. Davis, R. J. Hebert, E. S. Olcott, L. M. Johnson, N. T. Hargrett, P. A. Blake, and M. L. Cohen. 1983. Hemorrhagic colitis associated with a rare
20 *Escherichia coli* serotype. *N. Engl. J. Med.* 308:681.
5. Pai, C. H., R. Gordon, H. V. Sims, and L. E. Bryan. 1984. Sporadic cases of hemorrhagic colitis associated with *Escherichia coli* O157:H7. Clinical, epidemiologic, and bacteriologic features. *Ann. Intern. Med.* 101:738.
25
6. Borczyk, A. A., M. A. Karmali, H. Lior, and L. M. Duncan. 1987. Bovine reservoir for verotoxin-producing *Escherichia coli* O157: H7 [letter]. *Lancet* 1:98.
7. Blanco, J. E., M. Blanco, and J. Blanco. 1995. [Enterotoxigenic, verotoxigenic, and necrotoxicogenic *Escherichia coli* in food and clinical
30

- samples. Role of animals as reservoirs of strains pathogenic for humans]. *Microbiologia*. 11:97.
- 5 8. Ostroff, S. M., P. M. Griffin, R. V. Tauxe, L. D. Shipman, K. D. Greene, J. G. Wells, J. H. Lewis, P. A. Blake, and J. M. Kobayashi. 1990. A statewide outbreak of *Escherichia coli* O157:H7 infections in Washington State. *Am. J. Epidemiol.* 132:239.
- 10 9. Centers for Disease Control. 1993. Update: multistate outbreak of *Escherichia coli* O157:H7 infections from hamburgers-western United States, 1992-1993. *MMWR* 42:258.
- 15 10. Nathan, R. 1996. Japans *E.coli* outbreak elicits fear, anger. *Nature Medicine* 2:956.
11. Griffin, P. M., S. M. Ostroff, R. V. Tauxe, K. D. Greene, J. G. Wells, J. H. Lewis, and P. A. Blake. 1988. Illnesses associated with *Escherichia coli* O157:H7 infections. A broad clinical spectrum. *Ann. Intern. Med.* 109:705.
- 20 12. Karmali, M. A. 1989. Infection by verocytotoxin-producing *Escherichia coli*. *Clin. Microbiol. Rev.* 2:15.
13. Kovacs, M. J., J. Roddy, S. Gregoire, W. Cameron, L. Eidus, and J. Drouin. 1990. Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to *Escherichia coli* O157:H7. *Am. J. Med.* 88:177.
14. O'Brien, A. D. and R. K. Holmes. 1987. Shiga and Shiga-like toxins. *Microbiol. Rev.* 51:206.
- 30

15. Karch, H. and J. Bockemühl. 1989. [Infections by enterohemorrhagic Escherichia coli (EHEC): a clinical and microbiologic problem and a challenge for the public health service]. *Immun. Infekt.* 17:206.
16. Siegler, R. L. 1995. The hemolytic uremic syndrome. *Pediatr. Clin. North Am.* 42:1505.
17. Rowe, P. C., W. Walop, H. Lior, and A. M. Mackenzie. 1991. Haemolytic anaemia after childhood Escherichia coli O 157 .H7 infection: are females at increased risk? *Epidemiol. Infect.* 106:523.
18. 1996. Häufung von EHEC-Erkrankungen in Bayern. *Münchener Ärztliche Anzeigen* 23:14.
19. Doyle, M. P. 1991. Escherichia coli O157:H7 and its significance in foods. *Int. J. Food Microbiol.* 12:289.
20. Belongia, E. A., K. L. MacDonald, G. L. Parham, K. E. White, J. A. Koriath, M. N. Lobato, S. M. Strand, K. A. Casale, and M. T. Osterholm. 1991. An outbreak of Escherichia coli O157:H7 colitis associated with consumption of precooked meat patties. *J. Infect. Dis.* 164:338.
21. O'Brien, A. D., A. R. Melton, C. K. Schmitt, M. L. McKee, M. L. Batts, and D. E. Griffin. 1993. Profile of Escherichia coli O157:H7 pathogen responsible for hamburger-borne outbreak of hemorrhagic colitis and hemolytic uremic syndrome in Washington. *J. Clin. Microbiol.* 31:2799.
22. Beutin, L., D. Geier, H. Steinruck, S. Zimmermann, and F. Scheutz. 1993. Prevalence and some properties of verotoxin (Shiga-like toxin)-producing

- Escherichia coli in seven different species of healthy domestic animals. *J. Clin. Microbiol.* 31:2483.
23. Martin, M. L., L. D. Shipman, J. G. Wells, M. E. Potter, K. Hedberg, I. K. Wachsmuth, R. V. Tauxe, J. P. Davis, J. Arnoldi, and J. Tilleli. 1986. Isolation of Escherichia coli O157:H7 from dairy cattle associated with two cases of haemolytic uraemic syndrome [letter]. *Lancet* 2:1043.
24. Besser, R. E., S. M. Lett, J. T. Weber, M. P. Doyle, T. J. Barrett, J. G. Wells, and P. M. Griffin. 1993. An outbreak of diarrhea and hemolytic uremic syndrome from Escherichia coli O157:H7 in fresh-pressed apple cider [see comments]. *JAMA* 269:2217.
25. Read, S. C., C. L. Gyles, R. C. Clarke, H. Lior, and S. McEwen. 1990. Prevalence of verocytotoxigenic Escherichia coli in ground beef, pork, and chicken in southwestern Ontario. *Epidemiol. Infect.* 105:11.
26. Gannon, V. P., R. K. King, J. Y. Kim, and E. J. Thomas. 1992. Rapid and sensitive method for detection of Shiga-like toxin-producing Escherichia coli in ground beef using the polymerase chain reaction. *Appl. Environ. Microbiol.* 58:3809.
27. Bopp, C. A., K. D. Greene, F. P. Downes, E. G. Sowers, J. G. Wells, and I. K. Wachsmuth. 1987. Unusual verotoxin-producing Escherichia coli associated with hemorrhagic colitis. *J. Clin. Microbiol.* 25:1486.
28. Farmer, J. J. and B. R. Davis. 1985. H7 antiserum-sorbitol fermentation medium: a single tube screening medium for detecting Escherichia coli O157:H7 associated with hemorrhagic colitis. *J. Clin. Microbiol.* 22:620.

29. Scotland, S. M., B. Rowe, H. R. Smith, G. A. Willshaw, and R. J. Gross. 1988. Vero cytotoxin-producing strains of *Escherichia coli* from children with haemolytic uraemic syndrome and their detection by specific DNA probes. *J. Med. Microbiol.* 25:237.
30. Scotland, S. M., G. A. Willshaw, H. R. Smith, B. Said, N. Stokes, and B. Rowe. 1993. Virulence properties of *Escherichia coli* strains belonging to serogroups O26, O55, O111 and O128 isolated in the United Kingdom in 1991 from patients with diarrhoea. *Epidemiol. Infect* 111:429.
31. Russmann, H., E. Kothe, H. Schmidt, S. Franke, D. Harmsen, A. Caprioli, and H. Karch. 1995. Genotyping of Shiga-like toxin genes in non-O157 *Escherichia coli* strains associated with haemolytic uraemic syndrome. *J. Med. Microbiol.* 42:404.
32. Koneman, E. W., S. D. Allen, W. M. Janda, P. C. Schreckenberger, and C. W. j. Washington. 1992. The *Enterobacteriaceae*. In *Diagnostic Microbiology*. J.B. Lippincott Company, Philadelphia. 132-133.
33. Edelman, R. and N. F. Pierce. 1984. From the National Institute of Allergy and Infectious Diseases. Summary of the 19th United States-Japan Joint Cholera Conference. *J. Infect. Dis.* 149:1014.
34. Hart, C. A., R. M. Batt, and J. R. Saunders. 1993. Diarrhoea caused by *Escherichia coli*. *Ann. Trop. Paediatr.* 13:121.
35. Chapman, P. A. and C. M. Daly. 1993. Evaluation of non-radioactive trivalent DNA probe (LT, ST1a, ST1b) for detecting enterotoxigenic *Escherichia coli*. *J. Clin. Pathol.* 46:309.

36. Moseley, S. L., J. W. Hardy, M. I. Hug, P. Echeverria, and S. Falkow. 1983. Isolation and nucleotide sequence determination of a gene encoding a heat-stable enterotoxin of *Escherichia coli*. *Infect. Immun.* 39:1167.
37. Jerse, A. E., J. Yu, B. D. Tall, and J. B. Kaper. 1990. A genetic locus of enteropathogenic *Escherichia coli* necessary for the production of attaching and effacing lesions on tissue culture cells. *Proc. Natl. Acad. Sci. U. S. A.* 87:7839.
38. Taylor, D. N., P. Echeverria, O. Sethabutr, C. Pitarangsi, U. Leksomboon, N. R. Blacklow, B. Rowe, R. Gross, and J. Cross. 1988. Clinical and microbiologic features of *Shigella* and enteroinvasive *Escherichia coli* infections detected by DNA hybridization. *J. Clin. Microbiol.* 26:1362.
39. Prats, G. and T. Llovet. 1995. [Enteroinvasive *Escherichia coli*. Pathogenesis and epidemiology]. *Microbiologia.* 11:91.
40. Nataro, J. P., Y. Deng, D. R. Maneval, A. L. German, W. C. Martin, and M. M. Levine. 1992. Aggregative adherence fimbriae I of enteroaggregative *Escherichia coli* mediate adherence to HEP-2 cells and hemagglutination of human erythrocytes. *Infect. Immun.* 60:2297.
41. Cohen, M. B., J. A. Hawkins, L. S. Weckbach, J. L. Staneck, M. M. Levine, and J. E. Heck. 1993. Colonization by enteroaggregative *Escherichia coli* in travelers with and without diarrhea. *J. Clin. Microbiol.* 31:351.
42. Chang, P. P., J. Moss, E. M. Twiddy, and R. K. Holmes. 1987. Type II heat-labile enterotoxin of *Escherichia coli* activates adenylate cyclase in human fibroblasts by ADP ribosylation. *Infect. Immun.* 55:1854.

43. Pickett, C. L., D. L. Weinstein, and R. K. Holmes. 1987. Genetics of type Ila heat-labile enterotoxin of *Escherichia coli*: operon fusions, nucleotide sequence, and hybridization studies. *J. Bacteriol.* 169:5180.
44. Giron, J. A., M. S. Donnenberg, W. C. Martin, K. G. Jarvis, and J. B. Kaper. 1993. Distribution of the bundle-forming pilus structural gene (bfpA) among enteropathogenic *Escherichia coli*. *J. Infect. Dis.* 168:1037.
45. Karch, H., J. Heesemann, R. Laufs, A. D. O'Brien, C. O. Tacket, and M. M. Levine. 1987. A plasmid of enterohemorrhagic *Escherichia coli* O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. *Infect. Immun.* 55:455.
46. Nataro, J. P., M. M. Baldini, and J. B. Kaper. 1985. Detection of an Adherence Factor of Enteropathogenic *Escherichia coli* with a DNA probe. *J. Infect. Dis.* 152:560.
47. Watanabe, H., E. Arakawa, K. Ito, J. Kato, and A. Nakamura. 1990. Genetic analysis of an invasion region by use of a Tn3-lac transposon and identification of a second positive regulator gene, *invE*, for cell invasion of *Shigella sonnei*: significant homology of *invE* with *ParB* of plasmid P1. *J. Bacteriol.* 172:619.
48. Sasakawa, C., K. Komatsu, T. Tobe, T. Suzuki, and M. Yoshikawa. 1993. Eight genes in region 5 that form an operon are essential for invasion of epithelial cells by *Shigella flexneri* 2a. *J. Bacteriol.* 175:2334.
49. Echeverria, P., O. Serichantalerg, S. Changchawalit, B. Baudry, M. M. Levine, F. Orskov, and I. Orskov. 1992. Tissue culture-adherent *Escherichia*

- coli in infantile diarrhea. *J. Infect. Dis.* 165:141.
50. Schmidt, H., C. Knop, S. Franke, S. Aleksic, J. Heesemann, and H. Karch. 1995. Development of PCR for screening of enteroaggregative *Escherichia coli*. *J. Clin. Microbiol.* 33:701.
51. Faruque, S. M., K. Haider, M. M. Rahman, A. R. Abdul Alim, A. H. Baqui, Q. S. Ahmad, K. M. Hossain, and M. J. Albert. 1992. Evaluation of a DNA probe to identify enteroaggregative *Escherichia coli* from children with diarrhoea in Bangladesh. *J. Diarrhoeal. Dis. Res.* 10:31.
52. Yamamoto, T., P. Echeverria, and T. Yokota. 1992. Drug resistance and adherence to human intestines of enteroaggregative *Escherichia coli*. *J. Infect. Dis.* 165:744.
53. Savarino, S. J., A. Fasano, J. Watson, B. M. Martin, M. M. Levine, S. Guandalini, and P. Guerry. 1993. Enteroaggregative *Escherichia coli* heat-stable enterotoxin 1 represents another subfamily of *E. coli* heat-stable toxin. *Proc. Natl. Acad. Sci. U. S. A.* 90:3093.
54. Bennett, A. R., S. MacPhee, and R. P. Betts. 1995. Evaluation of methods for the isolation and detection of *Escherichia coli* O157 in minced beef. *Lett. Appl. Microbiol.* 20:375.
55. March, S. B. and S. Ratnam. 1986. Sorbitol-MacConkey medium for detection of *Escherichia coli* O157: H7 associated with hemorrhagic colitis. *J. Clin. Microbiol.* 23:869.

56. Kleanthous, H., N. K. Fry, H. R. Smith, R. J. Gross, and B. Rowe. 1988. The use of sorbitol-MacConkey agar in conjunction with a specific antiserum for the detection of Vero cytotoxin-producing strains of Escherichia coli O157. *Epidemiol. Infect.* 101:327.
57. March, S. B. and S. Ratnam. 1989. Latex agglutination test for detection of Escherichia coli serotype O157. *J. Clin. Microbiol.* 27:1675.
58. Beutin, L., S. Aleksic, S. Zimmermann, and K. Gleier. 1994. Virulence factors and phenotypical traits of verotoxigenic strains of Escherichia coli isolated from human patients in Germany. *Med. Microbiol. Immunol. Berl.* 183:13.
59. Stroehrer, U. H., L. Bode, L. Beutin, and P. A. Manning. 1993. Characterization and sequence of a 33-kDa enterohemolysin (Ehly 1)-associated protein in Escherichia coli. *Gene* 132:89.
60. Johnson, R. P., R. J. Durham, S. T. Johnson, L. A. MacDonald, S. R. Jeffrey, and B. T. Butman. 1995. Detection of Escherichia coli O157:H7 in meat by an enzyme-linked immunosorbent assay, EHEC-Tek. *Appl. Environ. Microbiol.* 61:386.
61. Padhye, N. V. and M. P. Doyle. 1991. Rapid procedure for detecting enterohemorrhagic Escherichia coli O157:H7 in food. *Appl. Environ. Microbiol.* 57:2693.
62. Clark, C. G., S. Johnson, and R. P. Johnson. 1995. Further characterisation of a monoclonal antibody reactive with Escherichia coli O157:H7. *J. Med. Microbiol.* 43:262.

63. Karmali, M. A., M. Petric, M. Winkler, M. Bielaszewska, J. Brunton, N. van de Kar, T. Morooka, G. B. Nair, S. E. Richardson, and G. S. Arbus. 1994. Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1. *J. Clin. Microbiol.* 32:1457.
64. Gunzer, F., H. Bohm, H. Russmann, M. Bitzan, S. Aleksic, and H. Karch. 1992. Molecular detection of sorbitol-fermenting Escherichia coli O157 in patients with hemolytic-uremic syndrome. *J. Clin. Microbiol.* 30:1807.
65. Bockemuhl, J., S. Aleksic, and H. Karch. 1992. Serological and biochemical properties of Shiga-like toxin (verocytotoxin)-producing strains of Escherichia coli, other than O-group 157, from patients in Germany. *Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis.* 276:189.
66. Smith, H. R., S. M. Scotland, G. A. Willshaw, C. Wray, I. M. McLaren, T. Cheasty, and B. Rowe. 1988. Vero cytotoxin production and presence of VT genes in Escherichia coli strains of animal origin. *J. Gen. Microbiol.* 134:829.
67. Karch, H. and T. Meyer. 1989. Evaluation of oligonucleotide probes for identification of shiga-like-toxin-producing Escherichia coli. *J. Clin. Microbiol.* 27:1180.
68. Jackson, M. P. 1991. Detection of Shiga Toxin-Producing Shigella dysenteriae Type 1 and Escherichia Coli by Using Polymerase Chain Reaction with Incorporation of Digoxigenin-11-dUTP. *J. Clin. Microbiol.* 29:1910.
69. Johnson, W. M., D. R. Pollard, H. Lior, S. D. Tyler, and K. R. Rozee. 1990. Differentiation of genes coding for Escherichia coli verotoxin 2 and the

- verotoxin associated with porcine edema disease (VTe) by the polymerase chain reaction. *J. Clin. Microbiol.* 28:2351.
70. Johnson, W. M., S. D. Tyler, G. Wang, and H. Lior. 1991. Amplification by the polymerase chain reaction of a specific target sequence in the gene coding for Escherichia coli verotoxin (VTe variant). *FEMS Microbiol. Lett.* 68:227.
71. Karch, H. and T. Meyer. 1989. Single primer pair for amplifying segments of distinct shiga-like-toxin genes by polymerase chain reaction. *J. Clin. Microbiol.* 27:2751.
72. Pollard, D. and W. M. Johnson. 1990. Rapid and Specific Detection of Verotoxin Genes in Escherichia Coli by the Polymerase Chain Reaction. *J. Clin. Microbiol.* 28:540.
73. Holland, P. M., R. D. Abramson, R. Watson, and D. H. Gelfand. 1991. Detection of specific polymerase chain reaction product by utilizing the 5'---3' exonuclease activity of *Thermus aquaticus* DNA polymerase. *Proc. Natl. Acad. Sci. U. S. A.* 88:7276.
74. Bassler, H. A., S. J. Flood, K. J. Livak, J. Marmaro, R. Knorr, and C. A. Batt. 1995. Use of a fluorogenic probe in a PCR-based assay for the detection of *Listeria monocytogenes*. *Appl. Environ. Microbiol.* 61:3724.
75. Livak, K. J., S. J. Flood, J. Marmaro, W. Giusti, and K. Deetz. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. *PCR. Methods Appl.* 4:357.

76. Förster, V. 1948. Zwischenmolekulare Energiewanderung und Fluoreszenz. *Annals of Physics (Leipzig)* 2:55.
- 5
77. Paton, A. W., J. C. Paton, P. N. Goldwater, and P. A. Manning. 1993. Direct detection of *Escherichia coli* Shiga-like toxin genes in primary fecal cultures by polymerase chain reaction. *J. Clin. Microbiol.* 31:3063.
78. Paton, A. W., J. C. Paton, P. N. Goldwater, M. W. Heuzenroeder, and P. A. Manning. 1993. Sequence of a variant Shiga-like toxin type-I operon of *Escherichia coli* O111:H-. *Gene* 129:87.
- 10
79. Paton, A. W., J. C. Paton, and P. A. Manning. 1993. Polymerase chain reaction amplification, cloning and sequencing of variant *Escherichia coli* Shiga-like toxin type II operons. *Microb. Pathog.* 15:77.
- 15
80. Gyles, C. L., S. A. De Grandis, C. MacKenzie, and J. L. Brunton. 1988. Cloning and nucleotide sequence analysis of the genes determining verocytotoxin production in a porcine edema disease isolate of *Escherichia coli*. *Microb. Pathog.* 5:419.
- 20
81. Gannon, V. P., C. Teerling, S. A. Masri, and C. L. Gyles. 1990. Molecular cloning and nucleotide sequence of another variant of the *Escherichia coli* Shiga-like toxin II family. *J. Gen. Microbiol.* 136:1125.
- 25
82. Schmitt, C. K., M. L. McKee, and A. D. O'Brien. 1991. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic *Escherichia coli* strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511. *Infect. Immun.* 59:1065.
- 30

83. Schmidt, H., M. Montag, J. Bockemuhl, J. Heesemann, and H. Karch. 1993. Shiga-like toxin II-related cytotoxins in *Citrobacter freundii* strains from humans and beef samples. *Infect. Immun.* 61:534.
84. Inoue, T., T. Tsuji, M. Koto, S. Imamura, and A. Miyama. 1993. Amino acid sequence of heat-labile enterotoxin from chicken enterotoxigenic *Escherichia coli* is identical to that of human strain H 10407. *FEMS Microbiol. Lett.* 108:157.
85. Franke, J., H. Schmidt, and H. Karch. 1994. Nucleotide Sequence Analysis of Enteropathogenic *Escherichia coli* (EPEC) Adherence Factor Probe and Development of PCR for Rapid Detection of EPEC Harboring Virulence Plasmids. *J. Clin. Microbiol.* 32:2460.
86. Yu, J. and J. B. Kaper. 1992. Cloning and characterization of the eae gene of enterohaemorrhagic *Escherichia coli* O157:H7. *Mol. Microbiol.* 6:411.
87. Kato, J., Y. Nishimura, R. Imamura, H. Niki, S. Hiraga, and H. Suzuki. 1990. New topoisomerase essential for chromosome segregation in *E. coli* [published erratum appears in *Cell* 1991 Jun 28;65(7):1289]. *Cell* 63:393.
88. Zhao, S., S. E. Mitchell, J. Meng, M. P. Doyle, and S. Kresovich. 1995. Cloning and nucleotide sequence of a gene upstream of the eaeA gene of enterohemorrhagic *Escherichia coli* O157:H7. *FEMS Microbiol. Lett.* 133:35.
89. Paton, A. W. and J. C. Paton. 1996. Enterobacter cloacae producing a shiga-like toxin II-related cytotoxin associated with a case of hemolytic-uremic syndrome. *J. Clin. Microbiol.* 34:463.

90. Witham, P. K., K. J. Livak, C. A. Batt, and C. T. Yamashiro. 1996. A PCR-based assay for detection of *Escherichia coli* shiga-like toxin genes in ground beef. *Appl. Environ. Microbiol* 62:1347.
91. Karch, H., C. Janetzki-Mittmann, S. Aleksic, and M. Datz. 1996. Isolation of Enterohemorrhagic *Escherichia coli* O157 strains from patients with hemolytic-uremic syndrome by using immunomagnetic separation, DNA-based methods, and direct culture. *J. Clin. Microbiol.* 34:516.
92. Huppertz, H. I., D. Busch, H. Schmidt, S. Aleksic, and H. Karch. 1996. Diarrhea in young children associated with *Escherichia coli* non-O157 organisms that produce shiga-like toxin. *J. Pediatrics* 128:341.

Article 34

49

Express Mail Label No.:
EL371022988US

Copy of Claims as Amended Under
Article 34

09/403690
514 Rec'd PCT/PTO 2 2 OCT 1999

International Patent Application: PCT/EP98/02341

Applicant: Bavarian Nordic Research Institute A/S

BN 25 PCT

July 12, 1999

5

New Claims

- 10 1. A method for detection of pathogenic enterobacteria in a sample comprising PCR amplification of DNA isolated from said sample using a set of oligonucleotide primer pairs allowing differentiation of at least two groups of pathogenic E.coli strains by amplification of a virulence factor/toxin gene characteristic for the
- 15 respective group of the pathogenic E. coli strains.
- 20 2. The method according to claim 1 wherein the set of oligonucleotide primer pairs comprises two or more primer pairs selected from
- a primer pair that hybridises to a gene encoding heat labile toxin, or heat stable toxin for amplification of a DNA sequence characteristic for enterotoxigenic E. coli;
 - 25 - a primer pair that hybridises to a gene encoding heat stable toxin for amplification of a DNA sequence characteristic for enteroaggregative E. coli;

50
2

5 - a primer pair that hybridises to the pCVD432 plasmid for amplification of a DNA sequence characteristic for enteroaggregative E.coli;

- a primer pair that hybridises to the inv-plasmid for amplification a DNA sequence contained in enteroinvasive E.coli;

10 - a primer pair that hybridises to the EAF plasmid, or the eae gene for amplification of a DNA sequence characteristic for enteropathogenic E.coli;

15 - a primer pair that hybridises to the genes encoding shiga-like toxin sltI or sltII for amplification of a DNA sequence characteristic for enterohemorrhagic E.coli.

3. The method according to claim 2 wherein

20

the primer pair that hybridises to the gene encoding heat labile toxin characteristic for enterotoxigenic E. coli is

LT-1: 5' GCG TTA CTA TCC TCT CTA TGT G 3' and

25 LT-2: 5' AGT TTT CCA TAC TGA TTG CCG C 3' ;

the primer pair that hybridises to the gene encoding heat stable toxin characteristic for enterotoxigenic E. coli is

5'
3'

ST-1: 5' TCC CTC AGG ATG CTA AAC CAG 3' and
ST-2a: 5' TCG ATT TAT TCA ACA AAG CAA C 3' ;

5

the primer pair that hybridises for the gene encoding heat stable toxin characteristic for enteroaggregative E. coli is

EASTI-1: 5' AAC TGC TGG GTA TGT GGC TGG 3' and
10 EASTI-2: 5' TGC TGA CCT GCC TCT TCC ATG 3' ;

the primer pair which hybridises to the pCVD432 plasmid is

EA-1: 5' CTG GCG AAA GAC TGT ATC ATT G 3' and
15 EA-2: 5' TAA TGT ATA GAA ATC CGC TGT T 3' ;

the primer pair which hybridises to the inv-plasmid is

EI-1: 5' TTT CTG GAT GGT ATG GTG AGG 3' and
20 EI-2: 5' CTT GAA CAT AAG GAA ATA AAC 3' ;

the primer pair which hybridises to the EAF plasmid is

EP-1: 5' CAG GGT AAA AGA AAG ATG ATA AG 3' and
25 EP-2: 5' AAT ATG GGG ACC ATG TAT TAT C 3' ;

the primer pair which hybridises to the eae gene is

EPeh-1: 5' CCC GGA CCC GGC ACA AGC ATA AG 3' and
30 EPeh-2: 5' AGT CTC GCC AGT ATT CGC CAC C 3' ;

52
4

the primer pair which hybridises to the gene encoding shiga-like toxin SltI is

5

SltI-1: 5' ATG AAA AAA ACA TTA TTA ATA GC 3' and

SltI-2: 5' TCA CYG AGC TAT TCT GAG TCA AGC 3';

the primer pair which hybridises to the gene encoding shiga-like toxin SltII is

10

SltII-1: 5' ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3'

and

SltII-2: 5' TCA GTC ATW AIT AAA CTK CAC YTS RGC AAA

15

KCC 3'

wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T.

20

4. The method according to claims 1 to 3 wherein a polymerase having additional 5'-3' exonuclease activity is used for the amplification of DNA, and an oligonucleotide probe labelled at the most 5' base with a fluorescent dye and at the most 3' base with a fluorescent quencher dye which hybridises within the target DNA is included in the amplification process; said labelled oligonucleotide probe being susceptible to 5'-3' exonuclease degradation by said polymerase to produce fragments that can be detected by fluorogenic detection methods.

25

5³
5'

5. The method according to claim 4 wherein the labelled oligonucleotide probe is specific for the respective virulence factor/toxin gene to be detected.

6. The method according to claim 5 wherein
10 the labelled oligonucleotide probe is specific for the detection of heat labile toxin characteristic for enterotoxigenic E. coli;

the labelled oligonucleotide probe is specific for the detection of heat stabile toxin characteristic for enterotoxigenic E. coli;

15 the labelled oligonucleotide probe is specific for the detection of heat stabile toxin characteristic for enteroaggregative E. coli;

the labelled oligonucleotide probe is specific for the detection of
20 pCVD432 plasmid;

the labelled oligonucleotide probe is specific for the detection of the inv-plasmid;

25 the labelled oligonucleotide probe is specific for the detection of the EAF-plasmid;

the labelled oligonucleotide probe is specific for the detection of the eae gene;

the labelled oligonucleotide probe is specific for the detection of shiga-like toxin StII gene;

5

the labelled oligonucleotide probe is specific for the detection of shiga-like toxin StIII gene.

10 7. The method according to claim 6 wherein

the labelled oligonucleotide probe for the detection of heat labile toxin characteristic for enterotoxigenic E. coli is

15 5' AGC TCC CCA GTC TAT TAC AGA ACT ATG 3';

the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enterotoxigenic E. coli is

20 5' ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3';

the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enteroaggregative E. coli is

25 3' ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3';

the labelled oligonucleotide probe for the detection of pCVD432 plasmid is

30 3' CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3';

55
7

the labelled oligonucleotide probe for the detection of the inv-plasmid is

5

5' CAA AAA CAG AAG AAC CTA TGT CTA CCT 3'

the labelled oligonucleotide probe for the detection of the EAF-plasmid is

10

5' CTT GGA GTG ATC GAA CGG GAT CCA AAT 3';

the labelled oligonucleotide probe for the detection of the eae gene is

15

5' TAA ACG GGT ATT ATC AAC AGA AAA ATCC 3';

the labelled oligonucleotide probe for the detection of shiga-like toxin StII gene is

20

5' TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3';

the labelled oligonucleotide probe for the detection of shiga-like toxin StII gene is

25

5' CAG GTA CTG GAT TTG ATT GTG ACA GTC ATT 3'.

8. The method according to claims 4 to 7 wherein the fluorescent reporter dye is 6-carboxy-fluorescein, tetrachloro-6-carboxy-fluorescein, or hexachloro-6-carboxy-fluorescein, and the fluorescent

30

quencher dye is 6-carboxytetramethyl-rhodamine.

5

9. The method according to claims 1 to 8 wherein the amplification process comprises 35 PCR cycles at a MgCl_2 concentration of 5.2 mmol, an annealing temperature of 55 °C and an extension temperature of 65 °C.

10

10. A set of primer pairs useful for PCR amplification of DNA of pathogenic enterobacteria allowing differentiation of at least two different groups of pathogenic E. coli strains by amplification of a virulence factor/toxin gene characteristic for the respective group of the pathogenic E.coli strains.

15

11. The set of primer pairs according to claim 10 comprising two or more primer pairs selected from

20

a primer pair that hybridises to a gene encoding heat labile toxin, or heat stable toxin of enterotoxigenic E. coli;

25

a primer pair that hybridises to a gene encoding heat stable toxin of enteroaggregative E. coli;

a primer pair that hybridises to the pCVD432 plasmid of enteroaggregative E. coli;

a primer pair that hybridises to the inv-plasmid of enteroinvasive E. coli;

5

a primer pair that hybridises to the EAF plasmid, or the eae gene of enteropathogenic E. coli;

10

a primer pair that hybridises to the gene encoding shiga-like toxin stII or stIII of enterohemorrhagic E. coli.

12. The set of primer pairs according to claim 11 wherein

15 the primer pair which hybridises to the gene encoding heat labile toxin of enterotoxigenic E. coli is

LT-1: 5' GCG TTA CTA TCC TCT CTA TGT G 3' and

LT-2: 5' AGT TTT CCA TAC TGA TTG CCG C 3' ;

20

the primer pair which hybridises to the gene encoding heat stabile toxin of enterotoxigenic E. coli is

ST-1: 5' TCC CTC AGG ATG CTA AAC CAG 3' and

25 ST-2a: 5' TCG ATT TAT TCA ACA AAG CAA C 3' ;

the primer pair which hybridises to the gene encoding heat stabile toxin of enteroaggregative E. coli is

30 EASTI-1: 5' AAC TGC TGG GTA TGT GGC TGG 3' and

EASTI-2: 5' TGC TGA CCT GCC TCT TCC ATG 3' ;

5 the primer pair which hybridises to the pCVD432 plasmid is

EA-1: 5' CTG GCG AAA GAC TGT ATC ATT G 3' and

EA-2: 5' TAA TGT ATA GAA ATC CGC TGT T 3' ;

10 the primer pair which hybridises to the inv-plasmid is

EI-1: 5' TTT CTG GAT GGT ATG GTG AGG 3' and

EI-2: 5' CTT GAA CAT AAG GAA ATA AAC 3' ;

15 the primer pair which hybridises to the EAF plasmid is

EP-1: 5' CAG GGT AAA AGA AAG ATG ATA AG 3' and

EP-2: 5' AAT ATG GGG ACC ATG TAT TAT C 3' ;

20 the primer pair which hybridises to the eae gene is

EPeh-1: 5' CCC GGA CCC GGC ACA AGC ATA AG 3' and

EPeh-2: 5' AGT CTC GCC AGT ATT CGC CAC C 3' ;

25 the primer pair which hybridises to the shiga-like toxin sltI gene is

Sltl-1: 5' ATG AAA AAA ACA TTA TTA ATA GC 3' and

Sltl-2: 5' TCA CYG AGC TAT TCT GAG TCA AGC 3' ;

30 the primer pair which hybridises to the shiga-like toxin sltII is

Site-1: 5' ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3'
and
Site-2: 5' TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA
KCC 3'

wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T.

13. A set of labelled oligonucleotide probes useful for detection of pathogenic enterobacteria by TaqMan™-PCR being specific for virulence factor/toxin genes of pathogenic E. coli strains.

14. The set of probes according to claim 13 comprising

a labelled oligonucleotide probe specific for the detection of heat labile toxin characteristic for enterotoxigenic E. coli;

a labelled oligonucleotide probe specific for the detection of heat stable toxin characteristic for enterotoxigenic E. coli;

a labelled oligonucleotide probe specific for the detection of heat stable toxin characteristic for enteroaggregative E. coli;

a labelled oligonucleotide probe specific for the detection of pCVD432 plasmid;

a labelled oligonucleotide probe specific for the detection of the inv-plasmid;

5

a labelled oligonucleotide probe specific for the detection of the EAF-plasmid;

10

a labelled oligonucleotide probe specific for the detection of the eae gene;

a labelled oligonucleotide probe specific for the detection of shiga-like toxin SttI gene;

15

a labelled oligonucleotide probe specific for the detection of shiga-like toxin SttII gene.

20

15. The set of probes according to claim 14 wherein

the labelled oligonucleotide probe for the detection of heat labile toxin characteristic for enterotoxigenic E. coli is

5' AGC TCC CCA GTC TAT TAC AGA ACT ATG 3';

25

the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enterotoxigenic E. coli is

5' ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3';

the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enteroaggregative E. coli is

5

5' ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3';

the labelled oligonucleotide probe for the detection of pCVD432 plasmid is

10

5' CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3';

the labelled oligonucleotide probe for the detection of the inv-plasmid is

15

5' CAA AAA CAG AAG AAC CTA TGT CTA CCT 3'

the labelled oligonucleotide probe for the detection of the EAF-plasmid is

20

5' CTT GGA GTG ATC GAA CGG GAT CCA AAT 3';

the labelled oligonucleotide probe for the detection of the eae gene is

25

5' TAA ACG GGT ATT ATC AAC AGA AAA ATC C 3';

the labelled oligonucleotide probe for the detection of shiga-like toxin SltI gene is

30

5' TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3'; —

the labelled oligonucleotide probe for the detection of shiga-like toxin
SltII gene is

3' CAG GTA CTG GAT TTG ATT GTG ACA GTC ATT 3'.

16. A kit useful for diagnosing an enterobacteria infection in
samples derived from a living animal body, including a human, by
TaqMan™-PCR method comprising a set of primer pairs according to
claims 10 to 12 and a set of oligonucleotide probes according to claims
13 to 15.

17. Use of the method according to claims 1 to 9 for diagnosing an
enterobacteria infection in a sample derived from a living animal
body, including a human, or for the detection of an enterobacteria
contamination of consumables, such as meat, milk and vegetables.

Please type a plus sign (+) inside this box → +

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

☐ Declaration
Submitted
with Initial
Filing

OR

☒ Declaration
Submitted after Initial
Filing (surcharge
(37 CFR 1.16 (e))
required)

Attorney Docket Number	20239-706
First Named Inventor	Klaus Pfeffer
COMPLETE IF KNOWN	
Application Number	09 / 403,690
Filing Date	October 22, 1999
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TaqManTM-PCR for the Detection of Pathogenic E. Coli Strains

the specification of which (Title of the Invention)

☐ is attached hereto
OR

☒ was filed on (MM/DD/YYYY) 04/21/1998 as United States Application Number or PCT International

Application Number PCT/EP98/02341 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/EP98/02341	PCT	04/21/1998	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
0451/97	Denmark	04/22/1997	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(a) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

(Page 1 of 2)

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☒

PTO/SB/01 (12-97)
 Approved for use through 9/30/00. CMB 0651-0032
 Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(d) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/EP98/02341	04/21/1998	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number ☐ Registered practitioner(s) name(s)/registration number listed below

Place Customer Number Bar Code Label Here

Name	Registration Number	Name	Registration Number
John W. Calkins	43,523	Emily M. Haliday	38,903
Darren E. Donnelly	44,093	Margaret Chu Ikaya	43,549
Carol M. Gruppi	37,341	Andrew A. Kumamoto	40,690
J. David Haddan	40,629	Suzanne Mack	44,888

☒ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto

Direct all correspondence to: ☐ Customer Number OR ☐ Correspondence address below

Name	Carol M. Gruppi		
Address	McCutchen, Doyle, Brown & Enersen, LLP		
Address	Three Embarcadero Center		
City	San Francisco	State	CA
ZIP	94111		
Country	U.S.A.	Telephone	(650) 849-4902
Fax	(650) 849-4800		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))	Family Name or Surname
Klaus	Pfeffer

Inventor's Signature			Date	1-2-00	
Residence: City	Munich	State	Germany	Citizenship	German
Post Office Address	Prinzregentenstr. 130 Lafoelcher jochel 3c				
Post Office Address					
City	Munich	State	Germany	ZIP	D-81825
Country	Germany				

☐ Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

